Chaperone-assisted E3 ligase CHIP: A double agent in cancer

Sunny Kumar, Malini Basu, Mrinal K. Ghosh

Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector-V, Salt Lake, Kolkata-700091 & 4, Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, India
Department of Microbiology, Dhruba Chand Halder College, Dakshin Barasat, South 24 Paraganas, West Bengal 743372, India

Received 25 May 2021; accepted 6 August 2021
Available online 1 September 2021

KEYWORDS
Chaperones (HSC70/HSP70 & HSP90); CHIP; Oncogene; Therapy; Tumor suppressor; Ubiquitin proteasome system (UPS)

Abstract The carboxy-terminus of Hsp70-interacting protein (CHIP) is a ubiquitin ligase and co-chaperone belonging to Ubox family that plays a crucial role in the maintenance of cellular homeostasis by switching the equilibrium of the folding-refolding mechanism towards the proteasomal or lysosomal degradation pathway. It links molecular chaperones viz. HSC70, HSP70 and HSP90 with ubiquitin proteasome system (UPS), acting as a quality control system. CHIP contains charged domain in between N-terminal tetratricopeptide repeat (TPR) and C-terminal Ubox domain. TPR domain interacts with the aberrant client proteins via chaperones while Ubox domain facilitates the ubiquitin transfer to the client proteins for ubiquitination. Thus, CHIP is a classic molecule that executes ubiquitination for degradation of client proteins. Further, CHIP has been found to be indulged in cellular differentiation, proliferation, metastasis and tumorigenesis. Additionally, CHIP can play its dual role as a tumor suppressor as well as an oncogene in numerous malignancies, thus acting as a double agent. Here, in this review, we have reported almost all substrates of CHIP established till date and classified them according to the hallmarks of cancer. In addition, we discussed about its architectural alignment, tissue specific expression, sub-cellular localization, folding-refolding mechanisms of client proteins, E4 ligase activity, normal physiological roles, as well as involvement in various diseases and tumor biology. Further, we aim to discuss its importance in HSP90 inhibitors mediated cancer therapy. Thus, this report concludes that CHIP may be a promising and worthy drug target towards pharmaceutical industry for drug development.

Copyright © 2021, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The functional state of proteins changes into malfunctioned state that results in serious ailments related to neurological, immune, cardiovascular systems and so on. As a prevention to these ailments, proteome will try to maintain the cellular homeostasis by two ways: (a) via proteasomal abasement of malfunctioned polypeptides and (b) via molecular chaperones mediated refolding. Cellular homeostasis is well maintained by proper balance between molecular chaperones and degradation machinery. Proteasome mediated abasement of malfunctioned polypeptides occur through ubiquitin proteasome system (UPS) or autophagy, which may works in an independent as well as synergistic manner. On the other hand, molecular chaperone (like HSP70, HSP90 etc.) behaves like an inspector that inspects and guides the folding machinery of proteome to recycle the malfunctioned polypeptides into their native form. Furthermore, molecular chaperones also assist the proteasome mediated degradation machinery along with their role in refolding machinery.

UPS is a multi-component system that regulates cellular threshold of malfunctioned and misfolded proteins or polypeptide through degradation in some bacteria, all eukaryotic cells, and archaea. Proteasome mediated protein degradation is catalyzed by series of enzymatic reactions. UPS involves three well known enzymes viz ubiquitin activating enzymes (E1s), ubiquitin conjugating enzymes (E2s) and ubiquitin ligase enzymes (E3s) (Fig. 1). The fourth one is known as ubiquitin chain elongating enzymes (E4s) that also found in UPS mediated degradation machinery. Ubiquitin (~8.5 kDa protein) is activated and conjugated to the E2 enzyme in the presence of ATP and E1 enzyme. Next, E2-ubiquitin complex is catalyzed in the presence of E3 ubiquitin ligases and transferred the ubiquitin molecule to the client protein. Peptide bonds are formed between specific lysine residues of client proteins and glycine residue in the carboxy terminus of ubiquitin molecule. E4 type of enzymes are also involved in the degradation machinery of UPS, responsible for polyubiquitination of client proteins. Seven types of ubiquitin lysine residues (K6, K11, K27, K29, K33, K48 and K63) are responsible for polyubiquitination. Polyubiquitinated client proteins are transferred and degraded by 26s proteasome.

Secondly, autophagy is another system of maintaining homeostasis of proteome by lysosome mediated proteolysis. Cellular abnormal proteins are automatically engulfed by phagosome called autophagosome. Autophagosome is further engulfed by a lysosome called auto-phagolysosome and is ultimately degraded through lysosomal hydrolysis. Furthermore, chaperones are also involved in lysosome mediated proteolysis viz, chaperone assisted selective autophagy (CASA) and chaperone-mediated autophagy (CMA). Over 500 E3 ligases are identified till date, here in this report, we are presenting an overview of up-to-date information of CHIP with special attention to its dual role in cancer and possible strategy for combinatorial use with HSP90 inhibitors.

CHIP: discovery, gene location, mutations, architectural alignment, tissues specific expression and sub-cellular localization

CHIP is playing important and selective role in the proteolysis of its client proteins through UPS. It is responsible for its dual action as a co-chaperone and an E3 ligase. It plays a major role in maintaining tissue homeostasis through maintenance of cellular threshold of client proteins including oncogenes and tumor suppressors by UPS/lysosomal degradation. In this section, we are providing a brief overview into its discovery, gene location, mutations, architectural alignment, tissues specific expression and its sub-cellular localization.

Discovery

Tetratricopeptide repeat (TPR) domain of CHIP is a key element responsible for protein—protein interactions. Based upon this fact Ballinger and his colleagues tried to find out the novel interacting proteins of TPR domain. Therefore, his team had started and successfully screened the human heart cDNA library with a fraction of cyclophilin-40 containing three TPR repeats. Through this screening, CHIP (a 34.8 kDa encoded protein) containing three TPR repeats at its N-terminus with Ubox domain at C-terminus was identified. Furthermore, amino acid arrangements of human CHIP have similarity with ~98% of mouse CHIP and ~60% of fruit fly CHIP. Surprisingly, Ubox domain regions of all three species have 87% amino acid similarity which indicates that 94 amino acid residues of Ubox domain of these species are similar and found to be highly conserved.

Gene location and mutations

Protein CHIP is encoded by gene STUB1 (STIP1 homology and U-box containing gene-1) which is located at p13.3 in chromosome number 16. In humans, it consists of 7 exons and 6 introns and translated into 303 amino acid containing protein. Till date, two isoforms of human CHIP containing 303 & 231 amino acids are reported with Uniprot IDs Q9UNE7-1 and Q9UNE7-2 respectively; but no experimental proofs are available for second isoform. Mutations are the changes in DNA sequence that can occur during copying of DNA or may be induced by some environmental factors (viz., UV light, smoking, chemical reagents etc.) that can produce serious illness. Recent reports state that STUB1 gene mutations are associated with various major diseases like Gorden Holmes syndrome (GHS), Machado-Joseph disease (MJD), and intracranial aneurysm (IA). GHS is characterized by hereditary cerebellar ataxia along with hypogonadotropic hypogonadism, whereas MJD is characterized by progressive cerebellar ataxia that results in loss of muscle co-ordination. Mutations in RNF216 and OTUD1 genes are also associated with GHS syndrome. Patients with these mutations have similar neurological characteristics to the
patients with STUB1 gene mutations. Furthermore, STUB1 gene mutation also attenuates E3 ligase activity and results into inhibition of proteasome mediated degradation of client protein hypoxia inducible factor-1 alpha (HIF1α). Till date, the limited number of studies has been performed over the STUB1 gene mutations and its involvement in the disease prognosis. Thus, more attention and focused research is needed in the area of STUB1 gene mutations borne diseases.

**Architectural alignment**

CHIP contains three TPR repeats at amino terminus, Ubox domain at its carboxyl terminus and both the structural units are integrated through a bridge called helical hairpin (HH) (Fig. 2A). Three sets of anti-parallel alpha helices are present in all three TPR repeats. The structural linkage between 1st and 2nd TPR repeats or 2nd and 3rd TPR repeats look like a ‘Knob and Hole’ structure. Hydrophobicity of this structure plays a key role in protein–protein interaction through each TPR unit. Association of client proteins with TPR domain of CHIP mostly occurs through molecular chaperones like HSC70/HSP70 and HSP90. Additionally, some reports revealed that TPR domain may also interact directly with client proteins in a chaperone independent manner. The extended seventh helix present at the end of third set of TPR repeat is connected to helical hairpin. Two extended long alpha helices containing ‘Helical Hairpin’ (HH) further associates
with Ubox domain. Ubox domain is organized as “Two beta hairpin - 1st alpha helix - 3rd beta hairpin - 2nd alpha helix”.49 Previously, E3 ligases are belonged to HECT and RING finger family. Later it was established that the E3 ligases cause poly-ubiquitination and found that it belongs to Ubox family.50,51 Ubox family is quiet similar to RING finger domain, only difference is that RING finger domain containing family is stabilized by Zn binding whereas Ubox family is stabilized by hydrogen bonding, and rest remains same.52,53

Tissues specific expression and subcellular localization

In general, protein CHIP is expressed in almost all type of tissues, but the expression levels differ in different tissues. Tissues having high expression of CHIP are skeletal muscle, heart, and brain whereas pancreas, lung, liver, placenta, and kidneys express CHIP at low levels. Generally, tissues with more metabolic activity and protein turnover have high CHIP expression level.36

At the time of discovery, CHIP was studied as a cytoplasmic protein, but as the research proceeds in last few decades various studies revealed that CHIP is widely distributed throughout the cell.28 (Fig. 2B). According to the literature CHIP is localized at various cellular regions and compartments but its expression is not fixed at any specific region or compartment of the cell. Client proteins of CHIP like CFTR,54 Pae1R55 and SGK156 co-localizes at endoplasmic reticulum (ER) for ubiquitination mediated proteasomal degradation. Furthermore, CHIP interacts with HSF1 and is localized within the nucleus.57 Some reports also revealed that co-localization of CHIP and its association with client proteins specifically occurs in nucleus rather than cytoplasm viz., p6558, RUNX159 and RUNX2.60 Another study indicates that CHIP also maintain homeostasis of mitochondrial proteins along with cytoplasmic proteins e.g., leucine rich repeat kinase 2 (LRRK2).61 CHIP further maintains the balance of those proteins which are present in golgi body viz., β-amyloid precursor protein (β-APP)62 and Tau.63 Additionally, proteins such as HSP7064 and α-synuclein65 interact with CHIP at cytoplasm. Thus, the literature review revealed that CHIP is mostly present in cytoplasm and partly distributed in the nucleus. TPR domain of CHIP is associated with client proteins via chaperones (viz., HSP70, HSP90, etc.) for maintenance of cellular threshold. So, in the next section we are interested to discuss the protein folding-refolding mechanism and CHIP mediated disposal mechanism of abnormal proteins.

Molecular chaperones and CHIP

Molecular chaperone (viz., HSC70/HSP70 and HSP90) contains ATPase domain and carboxyl terminus domain (CTD) at its N-terminus and C-terminus respectively, plays important role in proper folding of the newly synthesized polypeptides as well as refolding of the abnormal/misfolded proteins.66 CHIP through its N-terminus TPR domain
associates with the CTD of molecular chaperones (HSC70/HSP90). Refolding, proteasomal degradation and lysosomal degradation of abnormal or malfunctioned proteins depend on the interaction of molecular chaperones with the CHIP. Here, we classified the mechanism of association of E3 ligase CHIP with the molecular chaperones into three types: (a) HSC70/HSP70 dependent, (b) HSP90 dependent and (c) Direct mechanisms for degradation of client proteins (Fig. 3).

**HSC70/HSP70 dependent mechanism**

HSC70/HSP70 is a molecular chaperone; with the help of co-chaperones, it promotes either the proper refolding of the abnormal/unfolded/improperly folded proteins to their native states or CHIP mediated proteasomal or lysosomal degradation. HSC70/HSP40 complex promotes protein folding while E3 ligase CHIP competes with HSC70-HSP40 complex for degradation. Literature review suggests that chaperones viz., HSC70/HSP70 and HSP90 are actively competing with each other for re-folding of abnormal client proteins to their native form. Furthermore, in a normal physiological conditions ATP bound HSC70 is known for its low affinity for substrates and for its fast exchange rate while both the conditions are reverse for ADP bound HSC70/HSP70. Co-chaperones both HSC70 interacting protein (HIP) and HSP40 binds with the N-terminus ATPase domain of HSC70. HSP40 increases the ATPase activity of N-terminus domain of HSC70/HSP70 while HIP enhances the affinity of client proteins by stabilizing the ADP-bound form of HSC70/HSP70. ‘CHIP triage’ is a condition which decides chaperone bound client proteins either refolded back to its native state or degraded by proteasomal or lysosomal pathway. Additionally, recent reports revealed that chaperone and proteasome system compete, where chaperone system try to save proteins by proper folding while proteasome try to dispose-off the damaged proteins. Some reviews suggest that decision is also dependent on the state of misfolded protein or amount of abnormality in the protein. Chaperone system will try to refold the abnormal proteins, if not possible then proteasomal system will dispose-off the damaged proteins. CHIP attenuates the HIP functionality and inhibits HSP40 ATPase activity, that results in

---

**Figure 3** Molecular chaperones (HSP70/HSC70 and HSP90) dependent, independent and direct mechanisms of CHIP mediated degradation of client proteins. CHIP mediated degradation of client proteins through inhibition of either (A) HSP70/HSC70 mediated refolding; (B) HSP90 mediated refolding or, (C) Chaperones independent route for degradation of client proteins. Arrows indicate either positive (solid) or negative (T shaped) regulation.
the inhibition of HSP70 dependent refolding cycle.\textsuperscript{28} HSC70/ HSP70 bound client proteins may be degraded either through proteasomal degradation (BAG1 mediated) or lysosomal degradation (BAG3 mediated). BAG1 is a HSP70 associated co-chaperone that in a low concentration promotes the folding of proteins while in a high concentration it promotes the degradation of abnormal proteins through the 26S proteasome.\textsuperscript{83–85} Secondly, in some cases BAG3 recruits p62 to CHIP-HSC70/HSP70 complex. Due to this switching of degradation pathway from UPS to chaperone assisted selective autophagy (CASA) occur.\textsuperscript{85,90} Furthermore, BAG2 is a co-chaperone which inhibits the E3 ligase activity of CHIP that promotes the client protein HSP72 refolding by reducing its ubiquitination.\textsuperscript{91,92}

**HSP90 dependent mechanism**

Abnormal proteins are also either refolded back into their native functional state through HSP90 mediated refolding mechanism or may get degraded with the involvement of CHIP-HSP90 complex. According to the literature review, both CHIP-HSC70/HSP70 and CHIP-HSP90 complexes competes with each other, to prove their importance in maintaining proteome health. But according to documented reports CHIP-HSC70 complex plays a crucial role in majority of the abnormal proteins poly-ubiquitination and degradation rather than CHIP-HSP90 complex. Thus, these studies concludes that 80%–90% of CHIP client proteins degradation were documented with the involvement of CHIP-HSC70 complex while 10%–20% of client proteins degradation were documented through CHIP-HSP90 complex.\textsuperscript{51,94} In a HSP90 dependent mechanism, HSP90 associates with major co-chaperones viz., p23 and HOP.\textsuperscript{28,94–96} Co-chaperone p23 associates with ATPase like activity domain of HSP90 and responsible for reducing its ATPase like activity, that results in stabilization of the ATP bound state of HSP90.\textsuperscript{6} Co-chaperone HSC70-HSP90 organizing protein (HOP) consists of two TPR domains 1 at N-terminus while other at its C-terminus. HSC70-HSP90 organizing protein (HOP) acts like a bridge between HSC70 and HSP90, both the chaperones work in collaboration to maintain cellular integrity of proteome. N-terminal TPR domain of HOP associates with the CTD of HSC70/HSP70 while C-terminal TPR domain of HOP associates with CTD of HSP90.\textsuperscript{28,78} Furthermore, in HSP90 dependent mechanism ‘early pre-folding complex’ is formed with the association of HSC70, HSP40, HIP and client protein. Both TPR domains of HOP unites the HSP90 chaperone with the early pre-folding complex that is known as ‘intermediate pre-folding complex’.\textsuperscript{28,29} This complex also contains co-chaperones associated with the HSP90 viz., p23, immunophilins etc. along with early pre-folding complex. With the utilization of ATP (through hydrolysis), dissociation of intermediate pre-folding complex occurs and transfer the client protein to HSP90-p23 complex known as ‘mature pre-folding complex’ or ‘HSP90-p23-client protein’. Mature pre-folding complex refolds the abnormal polypeptides into their functional native form.\textsuperscript{28,94,97–99} E3 ligase CHIP and p23 have their different binding sites at HSP90 but they are allosteric inhibitor to each other. Thus, the outcome of HSP90 dependent mechanism for folding/degradation is totally dependent on the competition between CHIP and p23. Furthermore, multiple reports states that if the chaperones are not able to restore unfolded/misfolded proteins back into their native form, then E3 ligase CHIP hijacks the HSP90 mediated folding mechanism by inhibiting the functionality of co-chaperones viz., p23 and HOP. Finally, CHIP-HSC70 complex containing client proteins gets ubiquitinated in the presence of Ubc4/Ubc5 E2’s and degraded through the 26s proteasome.\textsuperscript{26,28,68}

**Direct mechanism**

E3 ligase CHIP also degrades abnormal proteins in a chaperone independent manner. CHIP by consuming its internal binding ability to ubiquitinate, degrade the abnormal proteins through E2,s (Ubc5/Ubc4) and 26s proteasome dependent route without any involvement of molecular chaperones.\textsuperscript{6} Abnormal proteins those having slow refolding mechanism are directly ubiquitinated and disposed by E3 ligase CHIP viz., smad1,\textsuperscript{100} smad3\textsuperscript{101} and CLEC-2.\textsuperscript{102} Till date, there is no such evidence found related to the conditions under which cellular proteome will undergo any selected mechanisms for the degradation of client proteins. Thus, this is one of the major questions left to answer, we want to draw attention of readers to study the conditions under which CHIP is selecting the way of client protein degradation out of these three mechanisms.

**Major functions of CHIP**

CHIP is documented for its well-established roles in physiology as well as in various human diseases.\textsuperscript{103} Here, we enlightened the fate of E2s - E3s interactions; crucial physiological functions of CHIP as E4 ligase and in DNA repair, maintenance of cellular protein homeostasis and metabolism.

**E2s and E3s interactions — rules the fortune of client proteins**

E2s and E3s are mostly responsible for deciding the fortune of a client protein along with the involvement of other components of UPS. Ubiquitin binding domain of E2 family enzymes is highly conserved. These E2s work with E3s in a collaborative manner and decides the fortune of client proteins, by addition of ubiquitin moiety to specific lysine residue.\textsuperscript{104} Previously, E2 enzyme UbcH5 was known to be associated with E3 ligase CHIP without any lysine (K) residue specificity and it played a critical role in CHIP mediated ubiquitination, but the motifs for this interaction were not studied. Afterwards in many other reports, researchers found that ubiquitination of client proteins in the presence of UbcH5 and CHIP occurred via K-48 linkage.\textsuperscript{105} Furthermore, E3 ligase CHIP is also reported to associate with dimeric Ubc13-Uev1A E2 complex, and this interaction leads to poly-ubiquitination of client proteins via K-63 linkage. Additionally, researchers have successfully found a common motif (Ser-Pro-Ala) responsible for interaction between E2 enzymes (viz., UbcH5, UbcH4 & Ubc13-Uev1A) and Ubox domain of E3 ligase CHIP.\textsuperscript{104} A specific case of client protein ubiquitination via CHIP in association with
both UbcH5 and UbcH6 E2 enzymes is also reported e.g. interferon regulatory factor 1 (IRF-1). Another group have found that eight E2 enzymes (viz., Ube2D1, Ube2D2, Ube2D3, Ube2E1, Ube2E2, Ube2E3, Ube2N and Ube2W) can specifically interact with Ubox domain of CHIP. Thus, CHIP can interact with a number of E2 enzymes and the outcome is too much complex and different for each interaction, hence much more research is needed in this area.

Can CHIP play like an E4 ligase?

Yes, CHIP can act like an E4 ligase and due to this it enhances the length of ubiquitin chain to the client proteins along with some other components of UPS. Most of the E3 ligases belongs to well-known families like HECT and RING, but in last two decades Ubox family of E3 ligases was documented as a third family represented as E4 ligases. UFD2 is the first Ubox containing protein having E4 ligase activity in yeast. A recent study revealed that CHIP is the first E3 ligase reported as an E4 ligase in mammalians e.g., CHIP mediates degradation of Parkin Associated Endothelin like Receptor (Pael receptor; Pael-R) along with Parkin in neurological disease Parkinson. Thus, this study clearly indicates that CHIP extends the ubiquitin length over Pael-R by acting as an E4 ligase and causes proteasomal degradation. Furthermore, E3 ligase CHIP also participates along with other E3 ligases in a mutual partnership.

CHIP plays an important role in DNA repair

Base excision repair (BER) is a crucial pathway to re-structure smaller breaks of DNA such as single-strand breaks, base damage, and base loss. X-ray repair cross complementing group-1 (XRCC1), DNA polymerase β and DNA Ligase IIIα provides a platform to produce error less transcription and replication of damaged DNA. As reported in recent literature, CHIP plays an important role to control cellular levels of BER proteins. XRCC1 protein helps in the formation of DNA repair complex over the damaged DNA and stabilizes the BER proteins. CHIP in a chaperone independent manner ubiquitinates and degrades the excess BER proteins that are not taking part in DNA repair complex. Still the mechanism by which CHIP differentiates between excess and chromatin associated BER proteins is not documented yet. Thus, these findings suggest that CHIP plays a significant role in DNA repair system.

CHIP maintains the cell/tissue homeostasis

CHIP plays a crucial role in the maintenance of cellular homeostasis in normal as well as under various stress conditions. In the heat stress condition, apart from ubiquitination of mis-folded proteins, CHIP has been reported to interact and selectively degrade the misfolded/denatured proteins in a HSP70 independent manner. Surprisingly, CHIP stabilizes the HSP70-protein complexes to number folds in the presence of CHIP rather than its absence. Molecular mechanism underlying the contradicting dual role of CHIP in normal vs stress conditions is not fully understood yet. Additionally, CHIP also plays a protective role for maintaining the proteome health in induced oxidative stress conditions. Recently, it has been found that CHIP degrades the endonuclease G in normal condition but not in H2O2 induced oxidative stress. Still the question is remains to be answered that how CHIP is differentiating the endonuclease G in normal and oxidative stress conditions. However, in response to osmotic stress, it has been reported that activation of p38MAPK, JNK and ERKs occurs in mammalian cells. In sorbitol induced osmotic stress, MEKK is dephosphorylated and results in CHIP mediated ubiquitination and degradation. Thus, these findings suggests that CHIP plays a protective role in maintaining homeostasis against heat stress, oxidative stress, and osmotic stress.

CHIP in major human diseases

As discussed earlier, CHIP has several well established various physiological roles. In the recent past, research was focused mainly on its involvement in the initiation and progression of various human diseases such as immune disorders, neurological disorders, aging, inflammatory disorders, bone remodeling and cardiovascular disorders.

Immune system

CHIP is expressed in various immune cells such as macrophages, dendritic cells, natural killer (NK) cells, T cells, B cells etc. But still its exact role has not been studied yet in these immune cells. CHIP has its role in regulation of nuclear factor kappa-light-chain-enhancer of activated B cells. Previously, it was known that CHIP interacts with NF-κB-inducing kinase (NIK) through HSP70 and gets ubiquitinated and degraded. As the era proceeds, another group has also found that formation of the HSP70/NIK/CHIP dimer/TRAF3 complex increases the ubiquitination and
degradation of NIK. They also found that degradation of NIK is not dependent on E3 ligase activity of CHIP. Thus, these studies suggest that CHIP forms a complex with other proteins including target proteins and degrades these clients without its E3 ligase activity.\textsuperscript{171,176,177} Toll like receptors play its crucial role in sensation and recognition of conserved structures of pathogen.\textsuperscript{178,179} It has been found that CHIP interacts with TLR4/9 and TLR2/7 complexes via HSP70 but does not interact with TL3.\textsuperscript{180} CHIP binds with HSP70/protein kinase C (PKC)-\textgreek{z}/SRC in TLR4/9 signaling pathway, resulting in K-63 dependent ubiquitination of both SRC and PKC-\textgreek{z}, which leads to the activation of NF-\kappa B signaling.\textsuperscript{180} Hence, these reports suggest that CHIP degrades TLR proteins and could affect the NF-\kappa B signaling pathway.

CHIP is also known to activate the protein kinases (viz., SRC/PKC-\textgreek{z},\textsuperscript{180} CARMA1\textsuperscript{181} and RIPK3\textsuperscript{182}). K-63 linked ubiquitin chain and KSP70 are involved in the CHIP mediated recruitment and activation of Src/PKC-\textgreek{z} protein kinase,\textsuperscript{180} while CHIP interacts with CARMA1 protein kinase through K-72 linked ubiquitin chain and promotes NF-\kappa B activation.\textsuperscript{181} Additionally, CHIP mediates the RIPK3 ubiquitination and degradation through lysosomal pathway.\textsuperscript{182} Further, CHIP regulates various nitric oxide synthases such as iNOS,\textsuperscript{183} nNOS\textsuperscript{184} and eNOS.\textsuperscript{185} It interacts with iNOS and nNOS through both HSP70 and HSP90 chaperones dependent manner\textsuperscript{186} and promotes K-48 linked ubiquitination and proteasomal degradation,\textsuperscript{186} while eNOS interacts through HSP90 dependent manner and degraded by UPS.\textsuperscript{186} It also plays an essential role in the proteasome mediated ubiquitination and degradation of signaling intermediate FADD.\textsuperscript{187} Further, it is found that CHIP mediates the regulation of various transcriptional factors (viz., HIF-1\textgreek{z},\textsuperscript{188,189} Foxp3,\textsuperscript{188,190} RFX-1,\textsuperscript{191} STAT4\textsuperscript{192,193} and Tat\textsuperscript{193}) that are involved in immune system. It interacts with both Foxp3 and RFX-1 through K-48 linked ubiquitin chain in HSP70 dependent manner and leads to its degradation by UPS\textsuperscript{188,190} while transcriptional factor HIF-1\textgreek{z} interacts with both K-48 and K-63 linked ubiquitin chain in HSP70 dependent manner and was found to be degraded through autophagy as well as UPS.\textsuperscript{188,189} CHIP also inhibits the HIV virus replication by proteasome mediated degradation of its viral component Tat.\textsuperscript{194} Thus, all these reports conclude that CHIP may play a significant role in the regulation of various immunological factors, transcriptional factors, protein kinases and various nitric oxide synthases in the immune system.

The body’s defense system can acknowledge and govern the tumorigenic cells primarily through the production of cancer specific cytotoxic T lymphocytes.\textsuperscript{194,195} In the body of a patient, the generation of T cells can be activated, eliminated, or controlled through the control of immune suppressive tumor micro-environment.\textsuperscript{195–197} The tumor microenvironment is too complex, mostly consisting of immune cells (viz., dendritic cells, neutrophils, T-reg cells, lymphocytes, monocytes and macrophages), adipose cells, fibroblasts, extracellular matrix and epithelial cells.\textsuperscript{198,199} Additionally, overwhelming of immune surveillance and extermination are hallmark of cancers.\textsuperscript{200,201} In the tumor micro-environment, these cells are functionally altered due to their interactions with each other, but the myeloid cells are plastic in nature in this context.\textsuperscript{198,202} Myeloid derived suppressor cells (MDSCs), neutrophils and tumor associated macrophages (TAMs) are the primary tumor associated myeloid cells and capable to suppress the immune system. The clear distinction between MDSCs and neutrophils in tumor is not well studied yet.\textsuperscript{203,204} However, monocytic-MDSCs are quite similar to TAMs, while polymorphonuclear-MDSCs are similar to tumor associated neutrophils.\textsuperscript{203} Furthermore, the release of granulocytic (G-CSF), macrophagic (M-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) by tumor cells results in granulo-macrophagoisis and extension of MDSCs in tumor microenvironment.\textsuperscript{205} The expansion of MDSCs in tumor microenvironment is also possible in a response to pro-inflammatory cytokines IFN-\gamma and IL-6.\textsuperscript{206,207} Additionally, various other cytokines (viz., IL-13 and IL-4) and TGF-\beta are also present in tumor microenvironment and promote the immunosuppressive role of MDSCs.\textsuperscript{208} On the other hand, TAMs involved in immune linked cancer development as well as in tumor suppression. Presence of M1 pro-inflammatory phenotype of macrophages in tumor microenvironment encourages the tumorigenesis at the site of chronic inflammation, while the presence of M2 phenotype of macrophages promotes the immunosuppressive role.\textsuperscript{209–212} Additionally, in most of the solid tumors, infiltration of macrophages is noticed\textsuperscript{199,209,212–215} and responsible for poor prognosis in breast cancer, glioblastoma and lung cancer.\textsuperscript{216–220} Thus, this review concludes that immune system tightly resembles the cancer development and tumor microenvironment. However, the role of CHIP in immunity has been well explained in the previous section. CHIP is present in various immune cells of tumor microenvironment (viz., macrophages, T-cells, neutrophils, NK cells etc.), but its exact role in these cells is not studied yet.\textsuperscript{192,173} Also, the direct role of CHIP in immune response mediated tumor development and in tumor microenvironment is not studied well. CHIP mediates the indirect regulation of inflammatory mediators, tumorigenic signaling molecules and microenvironment factors, suggesting that CHIP might have its role in immune response mediated tumor biology. As discussed earlier, CHIP mediates the regulation of TLR proteins in immune cells and results in the activation of NF-\kappa B signaling pathway in inflammation and tumor biology. This report does not mention the impact of NF-\kappa B signaling activation in tumor development and tumor microenvironment. But the activation of NF-\kappa B signaling suggests that CHIP might have its impact on the correlation between immune response and tumor development.\textsuperscript{171,176–178,180} Recently a research group has studied the Parkin mediated regulation of CHIP-IRF1 axis which controls the anti-tumorigenic immune response and found that removal of mitochondrial membrane protein Fam73b leads to the activation of IL-12 and causes the switching of mitochondrial morphology from fusion to fission. The mitochondrial dynamics is found to affect the parkin gene expression and its mitochondrial recruitment. E3 ligase Parkin inhibits the CHIP-IRF1axis and suggests the anti-tumorigenic immune response.\textsuperscript{138} Thus, all these reports suggest that CHIP has some indirect and unknown role in immune response mediated tumor development and tumor microenvironment. We
would like to draw the kind attention of researchers to study the impact of CHIP upon the correlation between immune responses and tumor biology.

Aggresome formation and maturation

Cellular toxicity due to mis-folded proteins is operated by three different mechanisms. Firstly, mis-folded proteins try to get re-folded back to their nascent form with the help of chaperones. Secondly, if not possible to refold back, then it leads to its lysosome or proteasome mediated degradation. In the last mechanism, sequestration of mis-folded proteins/poly-peptides occurs into juxtanuclear detergent-insoluble inclusion bodies called aggresome.\textsuperscript{221,223} Recently, it was found that CHIP plays another vital role in the formation of cellular protein aggregates and inhibits aggresome maturation.\textsuperscript{54,224} Thus, CHIP may play distinct role in aggresome formation and maturation.

Neurodegeneration

Neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and Huntington’s disease occurs due to accumulation of non-functional, toxic and misfolded protein aggregates.\textsuperscript{225} In the removal of these misfolded protein aggregates of neurodegenerative diseases various E3 ligases and proteasomes are involved.\textsuperscript{206,227} One of the E3 ligase CHIP plays an important role to maintain neural homeostasis during the involvement of HSP70, HSC70 and HSP90.\textsuperscript{62,225,228} It has been reported that CHIP plays an essential role in the ubiquitination of various important factors of these neurodegenerative diseases such as Tau and APP in AD,\textsuperscript{62,227,228} Ataxin-1 & Ataxin-3 in type-1 & type-3 spino-cerebellar ataxia\textsuperscript{229,230} and malin in Lafora disease.\textsuperscript{231,232} Mechanism of CHIP mediated protection of neural system from toxicity caused by misfolded protein aggregates is not yet fully understood. However, it has been reported that limited expression of CHIP causes neural toxicity due to protein aggregation, accumulation, and induction of stress.

Inflammation, bone remodeling and skin diseases

CHIP contributes in controlling inflammation through regulation of interleukins 4α receptor (IL-4Rα)\textsuperscript{260} TNFα\textsuperscript{261} and NF-κB.\textsuperscript{262,263} Both interleukins- 3 and 4 signaling pathways are regulated through a common IL-4Rα receptor. CHIP interacts with IL-4Rα and leads to its UPS dependent degradation that suggests CHIP regulates the inflammation by the degradation of IL-4Rα.\textsuperscript{264,265} In arthritis patients and inflammatory diseases, TNFα level is high which leads to the degeneration of bones and cartilages. Osterix is a novel zinc finger-containing transcription factor that is essential for osteoblast differentiation and bone formation. A recent study suggests that upon CHIP up-regulation, TNFα inhibits osteoblast differentiation due to degradation of osterix.\textsuperscript{261} CHIP has its magnificent role in bone remodeling by degradation of various signaling molecules such as multiple SMAD proteins,\textsuperscript{266,267} RUNX2\textsuperscript{178,268} and TRAF family members viz., TRAF2, TRAF5, TRAF6.\textsuperscript{261,269–271} CHIP mediates the degradation of multiple SMAD proteins and thus regulates TGFβ pathway and bone morphogenetic protein (BMP) signaling.\textsuperscript{266,267} Induction of RUNX2 degradation occurs by CHIP that results in inhibition of osteoblast differentiation. NF-κB signaling has its well-known role in regulation of bone remodeling.\textsuperscript{128,268} CHIP degrades various TRAF family proteins and leads to inhibition of NF-κB signaling. Authors also found that nuclear translocation of NF-κB subunit p65 is increased upon STUB1 gene knock out in mice, resulting in reduction of osteoblast formation.\textsuperscript{263,269–271} Thus, these findings suggest that CHIP may play a significant role in inflammation and bone remodeling. On the other hand, CHIP plays a tremendous role in skin diseases by regulating cytoskeleton protein (keratins\textsuperscript{272}) and enzyme (NUCB1\textsuperscript{273}). Thus, all these findings indicate that CHIP may play significant roles in inflammation, bone remodeling and skin diseases.

Aging and development

Aging is a phenomenon which is characterized by structural and functional changes in all tissues and organs, resulting in reduction of regenerative capacity of tissues. In the later stage of aging, increment in production and accumulation of toxic protein aggregates occurs due to reduction in chaperones and proteasomal activity.\textsuperscript{228,274} Recent studies reveal that HSP70 has a direct link with aging.\textsuperscript{275,276} CHIP plays its beneficiary role in cellular hemostasis as well as in the control of aging process. It has been reported that in STUB1 deficient mice, lagging related biomarkers are increased due to accumulation of toxic proteins. Expression of leucine rich repeat kinase-2 (LRRK2) is high in STUB1 KO mouse model of PD. Level of LRRK2 is down-regulated due to increased expression and activation of cellular CHIP.\textsuperscript{225,240} Additionally, CHIP controls aging induced hyper-activated biomarkers such as Sirtuin 6 (SIRT6)\textsuperscript{278,279} and insulin receptor.\textsuperscript{145,280} Thus, these findings concludes that CHIP plays an essential role in controlling the aging process. Further, CHIP regulates various developmental processes by regulating signaling intermediates (Ca\textsuperscript{2+}/S100);\textsuperscript{281} transcriptional factors (myocardin\textsuperscript{282} and RUNX2\textsuperscript{260}); various enzymes (viz., NEK10, 283
and cytoskeleton proteins (viz., PKC, PDE5, and mTOR).
All together these findings conclude that CHIP plays a necessary role in aging and developmental processes in the human body.

Aging is highly correlated with cancer where aging is considered as a pro-tumorigenic state. Recently a couple of reports CHIP has been linked with cardiac diseases.\textsuperscript{298} This report suggests that CHIP is an important E3 ligase responsible for aging mediated pro-tumorigenic condition.\textsuperscript{293–299} However, chaperone associated E3 ligase CHIP has its extensive role as an anti-aging agent as discussed in earlier section. But none of these reports has clearly discussed the role of CHIP on aging mediated tumor development and in tumor microenvironment, and hence requires immediate attention.

Cardiovascular diseases

CHIP is highly expressed in heart tissues and behaves like a cardio-protective agent in heart diseases.\textsuperscript{28} Recently in a couple of reports CHIP has been linked with cardiac crashes. Accumulation of p53 in cardiac myocytes is the major feature of ischemic heart diseases.\textsuperscript{298} This report suggests that CHIP is an important E3 ligase responsible for p53\textsuperscript{299,300} and HIF-1α\textsuperscript{300} degradation. In the coronary occlusion condition, hypoxia is generated in cardiac myocytes that leads to the up-regulation of HIF-1α and down-regulation of CHIP expression and eventually the ischemic heart diseases.\textsuperscript{300} Overexpression of CHIP in combination with HSP90 inhibition (using 17AAG) leads to the cardioprotective effects.\textsuperscript{299} Further, in various reports CHIP has been studied as a beneficiary factor in cardiac diseases by degrading its client proteins classified as transcription factors (viz., ICER\textsuperscript{301} and NFATc3\textsuperscript{302}); cytoskeleton proteins (viz., HERG,\textsuperscript{303} Kv1.5\textsuperscript{304} and NaCl co-transporter\textsuperscript{305}); and signaling intermediates (viz., Gs\textsuperscript{306} and SHP-1). Thus, CHIP is an eminent cardio-protective agent.

Currently, various of chemotherapeutic agents have been developed and are used in clinical practice for cancer therapy viz., antimetabolites, platinum-based agents, alkylating agents, anti-microtubular agents, anthracyclines and antitumor antibiotics. Additionally, various targeting agents (viz., immune checkpoint inhibitors, small molecule inhibitors and HER2 inhibitors) are also developed for cancer therapy. However, the cardiotoxicity is noticed as a prominent side effect of these chemotherapeutics. Cardiotoxicity induced by chemotherapeutics may include cardiac cell damage, abnormalities in cardiac impulse conduction, reduction in left ventricular ejection rate and fraction, disturbance in blood pressure etc.\textsuperscript{308–313} Sunitinib malate is a small molecule tyrosine kinase inhibitor having anti-tumorigenic activity against gastrointestinal, pancreatic, neuroendocrine tumors and advanced renal cell carcinoma. The use of sunitinib is noticed to produce cardiotoxic side effects such as vascular disturbances in thromboembolic events, hypertension, heart failure and occasionally may leads to death. In the management of these side effects, various other pharmacological agents are currently used. For thromboembolic events, low molecular weight heparins (LMWH), rivaroxaban and edoxaban are preferred; to manage hypertension, angiotensin inhibitors and calcium channel blockers are preferred; and in the management of heart failure clinicians are preferring angiotensin inhibitors and cardio-selective beta blockers.\textsuperscript{308} Recently, a research group has demonstrated the use of geldanamycin (HSP90 inhibitor) to attenuate the sunitinib induced cardiotoxicity and found significant reduction in sunitinib induced cytotoxicity in rat H9C2 cardiomyocytes. They also tried with the use of other HSP90 inhibitors such as tanezumab, BIBO21 and gane-tespib in sunitinib induced heart toxicity model. Sunitinib originated cardiotoxicity is due to the induction of autophagy in H9C2 cells, while in combination with geldanamycin sunitinib induced autophagy was inhibited and induced the degradation of various autophagy associated proteins viz., Atg7, ULK1 and Beclin-1. It also demonstrated the inhibitory effects of geldanamycin in sunitinib induced cardiotoxicity in pluripotent stem cell derived cardiomyocytes. Hence, these results conclude that HSP90 inhibitors in combination with sunitinib may be a potential strategy to attenuate the cardiotoxicity of sunitinib.\textsuperscript{314} Furthermore, doxorubicin (DOX, an anthracycline based antibiotic) is also preferred in chemotherapy against prostate, cervix, breast, brain cancers and in Hodgkin’s lymphoma. Lower ventricle failure, arrhythmia and heart failure are primarily noticed cardio-toxic side effects in DOX treatment. Often clinicians prefer antiarrhythmic agents to manage DOX-induced arrhythmia, while beta blocker (carvedilol) and ACE inhibitor (enalapril) are much preferred to manage doxorubicin induced heart failure and ventricular dysfunction.\textsuperscript{306} Recently, a research group has studied the inhibitory action of 17-AAG in DOX-induced cardiotoxicity.\textsuperscript{315} And another group has demonstrated that doxorubicin induced cardiotoxicity may be attenuated upon the treatment of cardiomyocytes with 17-DMAG.\textsuperscript{316,317} Thus, these studies suggest that DOX-induced cardiotoxicity may be nullified, if the HSP90 inhibitors were used in combination. At present, HSP90 inhibitors in combination with DOX and sunitinib is only studied to prevent their cardiotoxicity.\textsuperscript{314,315,317} Thus, researchers and clinicians should explore more on this strategy with an objective to control cardiotoxicity of cancer chemotherapeutics.

We have enlightened above the responsibility of CHIP in normal physiology as well as in several diseases such neurodegenerative disorders, immunological disorders, cardiac disorders, aging, inflammatory disorders, bone remodeling and skin diseases to maintain the protein quality and control the cellular threshold of clients. But in the recent era of CHIP, it is studied for its fundamental role as a double agent in cancer and most of the substrates reported till date are involved in cancer initiation and progression. Mostly, CHIP is documented for its tumor suppressor role over its oncogenic actions. Further, we are interested to focus on clinical significance of CHIP in various cancers and its involvement as a double agent.
CHIP: a double agent in cancer

In the year of 1998, CHIP was screened and discovered in heart tissue by Ballinger and his group. It plays a critical role through maintenance of protein quality and control the cellular threshold of client proteins. Its role is totally unpredictable but depends upon the status of target proteins. After its discovery, several substrates of CHIP were documented, and its involvement was found in several human diseases as discussed in the earlier sections of this review. Here authors retrieved almost all the documented substrates till December 2020 and have represented all of them in a pictorial timeline, according to the year of discovery (Fig. 4).

CHIP has its wide variety of functions in normal physiology as well as in several diseases including cancer. Also, the documented client proteins were also classified in context of various disease perspectives (Table S1). Surprisingly, it is found that in the last decade, most of its substrates were documented to be involved in cancer. It was found to have a double role (either as a tumor suppressor or as an oncogene) in many cancers. Hence, we classified the substrates further according to the hallmarks of cancer200,318,319 in the context of its role as an oncogene and a tumor suppressor24,172,320 (see Fig. 5). Here, we have tried to focus on both the opposing roles of CHIP in cancerous scenario.

Acts as a tumor suppressor

In a pioneer study CHIP has been found as a key mediator that regulates the breast cancer progression. They found that CHIP level is negatively correlated with tumor growth and metastasis in a breast cancer model of nude mice. In support of this pioneer study, series of reports have been published showing the active involvement of CHIP in different cancers; this certainly creates an important debate. These reports suggest that CHIP may play as a tumor suppressor via interacting and proteasomal mediated degradation of onco-proteins. Here, in this study we made a survey of reported substrates of CHIP in cancer till date and classified them under various hallmarks of cancer (Fig. 5). In few reports, it has been observed that CHIP may acts as a tumor suppressor with the inhibition of inflammatory hallmark of cancer. In the aspect of tumor suppressive action of CHIP, it interacts with few inflammatory mediators, leading to ubiquitination and proteasome dependent degradation of target proteins viz., MIF, MAST1, CD166, FGFR3, and ISG15. Often, MIF-HSP90 chaperone complex is reported as a highly stabilized complex in various human cancers and responsible for tumor aggressiveness. Inhibition of HSP90 chaperone with 17AAG or HSP90 specific siRNA, promotes the E3 ligase CHIP mediated MIF degradation and leads to the inhibition of inflammatory characteristics in breast cancer model. CHIP mediated regulation of FGFR3 also occurs through the same mechanism. Additionally, microtubule-associated serine/threonine kinase 1 (MAST1) is studied as a responsible factor for cisplatin resistance in multiple human cancers. Recently, through proteomic analysis a research group has shown HSP90B chaperone as an interacting partner and stabilizing factor of MAST1. Further, they have found E3 ligase CHIP mediates the degradation of MAST1, upon the inhibition of HSP90B chaperone and results in the improvement of cisplatin effectiveness. Thus, this report suggests that HSP90 inhibitors in combination with cisplatin may be an effective strategy to overcome the cisplatin resistance. Recently, a research group studied CD166 in head and neck (H&N) cancer to investigate the CHIP linked molecular mechanism and found that CHIP mediates the degradation of CD166 and leads to the inhibition of inflammatory characteristics of H&N cancer. Thus, all these mechanistic reports clearly indicate that how CHIP may govern the inflammatory hallmark of tumor biology.

Similarly, CHIP is negatively correlated with various substrates viz., AXL, C-ErbB2/Neu, C-ABL, EGFR, ECH, EZH2, PRMT5, OCT4 and trans-glutaminase 2 results in the inhibition of tumor progression. Tyrosine kinase AXL receptor is highly expressed in multiple cancers and primarily responsible tumor progression. 17AAG dependent

---

Figure 4  Timeline for client proteins of CHIP. The figure depict the timeline of all documented client proteins of CHIP identified till December 2020.
inhibition of HSP90 chaperone leads to destabilization of AXL through CHIP mediated degradation, resulting in inhibition of tumor progression. Furthermore, tyrosine kinase inhibitor imatinib is a primary drug in myeloid leukemia but resistant in chronic myeloid leukemia patients due to high expression of BCR-ABL protein. Chk1 inhibitors (AZD7762 and MK-8776) as well as oridonin promote CHIP mediated degradation of BCR-ABL protein in chronic myeloid leukemia cells. Thus, targeting Chk1 or treatment with oridonin may help to overcome the imatinib resistance in chronic myeloid leukemia patients.

CHIP acts as a tumor suppressor through degradation of EGFR and its mutated forms those highly expressed in cancer. Next, CHIP can degrades oncogenic protein enhancer of zeste homolog 2 (EZH2). A novel EZH2 targeting molecule (derivative of gambogenic acid) is recently identified which covalently binds EZH2 at cysteine and promotes CHIP mediated degradation. Through SILAC based proteomics study a research group has found pyruvate kinase isozyme M2 (PKM2), an important regulatory factor for aerobic glycolysis (Warburg effect) and tumorigenesis, to be a novel target protein of E3 ligase CHIP and maintain an inverse correlation in ovarian carcinoma. Thus, the Warburg effect is regulated through CHIP mediated degradation of PKM2.

Additionally, CHIP promotes the apoptosis of tumor cells by ubiquitination and degradation of target proteins C-terminal binding protein 2 (CtBP2), C-terminal binding protein (CtBP), NPM-ALK, mutant p53, ER-alpha, mutant EGFR, eIF5A, hTERT, IRS4, MLK3, p85 subunit of PI3K, and SRC-3. MLK3 and MLK4β are components of MAP kinase signaling pathway which regulates cellular responses like proliferation, invasion, and apoptosis. Expressions of MLK3 and MLK4β are inversely correlated with osmotic stress/thermo stress/HSP90 inhibition due to CHIP mediated degradation which results in decreased cellular proliferation of ovarian cancer cells. Similarly, inhibition of HSP90 chaperone with 17AAG promotes degradation of anaplastic lymphoma kinase (ALK) and PTK6, suggesting tumor suppressive action of CHIP.

In the screening of its substrates, it was also found that CHIP inhibits metastasis of tumor cells by targeting CK2β,Slug, SNPH, TRAF2, TAL1/Scl, MZF1, p65, SNAIL, and snail. Activation of protein kinase CK2 promotes the TGFβ mediated epithelial mesenchymal transition. CHIP mediates the degradation of CK2β and results in inhibition of invasion and migration in tumor cells. Additionally, GSK3β mediates the Slug phosphorylation that leads to its degradation by CHIP and prevent metastasis in lung cancer. CHIP negatively regulates the NF-κB signaling by downregulating TRAF2. A recent report indicated that CHIP and snail both are inversely correlated in ovarian carcinoma. CHIP inhibits EMT through downregulation of snail, a characteristic marker protein of EMT. Thus, CHIP acts as a tumor suppressor by inhibiting metastatic hallmark of cancer.

Additionally, CHIP promotes the apoptosis of tumor cells by ubiquitination and degradation of target proteins CtBP2, DDIAS, and mutant p53. C-terminal binding protein 2 (CtBP2) and DNA damage induced apoptosis suppressor (DDIAS) are involved in cellular apoptosis, migration.

Figure 5  Pie-in-pie chart of CHIP as a double agent in the context to cancer. CHIP client proteins classified according to the hallmarks of cancer and its dual role as a tumor suppressor (left hand sided pie chart) and as an oncogene (right hand sided pie chart) explained.
and tumorigenesis. These proteins are highly expressed in many cancers with low expression of CHIP. It was reported that overexpression of CHIP downregulates the CtBP2 and DDIA5 proteins. CHIP mediated ubiquitination and degradation of Androgen Receptor (AR) results in mitotic arrest of prostate tumor cells. CHIP targets PI3K/Akt and inhibits the survival power of tumor cells. Oncoprotein c-Myc plays its crucial role in oncogenesis. Our research group identified that CHIP targets and degrades c-Myc and results in the inhibition of cell cycle progression. Altogether, many reports clearly indicate that CHIP can act as a tumor suppressor in multiple cancer scenarios. CHIP mRNA and protein levels are differentially maintained in normal and breast cancer tissues. CHIP level is negatively correlated with the increment of breast cancer malignancy and overall survival of high CHIP expressing tumor bearing patients is much higher than the low CHIP expressing tumor bearing patients. Further, both mRNA and protein expression levels of CHIP are negatively correlated with its usual level in normal gastric tissues. Thus, all these reports suggest that CHIP can act as a tumor suppressor.

**Acts as an oncogene**

In adverse to above mentioned reports, CHIP is also seen to act like an oncogene in few of other reports. CHIP promotes proliferation and survival of tumor cells after the degradation of its substrates viz., PTEN, FOX1, HIPK2, p14ARF and p21 which are mainly engaged in tumor suppression and apoptosis. Transcriptional factor FOXO1 is responsible to control the cellular proliferation and survival. Its cellular level and activity are controlled by UPS and PI3K/Akt. Overexpression of CHIP with TNF alpha treatment downregulates the FOXO1 and promotes the PI3K/Akt pathway mediated cellular proliferation and survival. Conversely, upon its knockdown, FOXO1 gets stabilized and results in the inhibition cellular proliferation and survival. Serine/threonine kinase HIPK2 plays crucial roles in DNA damage response and development. PARP1 regulates the HIPK2 protein stability. Furthermore, CHIP promotes the HIPK2 degradation in a PARP1 independent manner and suggests its oncogenic role. HSP90 in combination with CHIP promotes the lysosomal pathway mediated degradation of p14ARF. While the knockdown of CHIP in combination with HSP90 inhibition gives converse results in non-small cell lung cancer. Knockdown of CHIP inhibits degradation of p21 which targets the various stress related proteins and ultimately enhances the sensitivity of lung cancer cells towards radiotherapy. CHIP-HSP70-p21 axis may be potential target to improve the efficacy of radiotherapy.

Similarly, CHIP is also reported to promote metastasis after the ubiquitination and degradation of SMAD proteins. A research group using surface plasmon resonance study established that the SMAD proteins physically interacts with CHIP. Further, another group observed that the overexpression of CHIP mediates downregulation of SMAD proteins and results in inhibition of BMP signaling. Prolin-1 is an important mediator of actin polymerization and regulates the cellular migration. Lower expression of prolin-1 is correlated with several malignancies. In recent study, poly-ubiquitination and degradation of prolin-1 is studied in the CHIP overexpressed breast cancer cells which results in the enhancement of cellular migration and metastasis. Converse results were obtained upon CHIP knockdown. Thus, all these reports indicate that CHIP may act like an oncogene by promoting metastatic hallmark of cancer. Subsequently, CHIP is found to increase cellular differentiation but not proliferation after the proteasome-mediated degradation of Menin. In another finding, CHIP mediates degradation of LKB1 and causes increment in the cellular proliferation, while TAP73α degradation causes anti-apoptotic action, and both finally leads to oncogenes. Thus, all these reports clearly suggest that CHIP can play as an oncogene in several cancers.

Significantly high expression of CHIP was found in a metastatic lymph nodes of esophageal squamous cell carcinoma (ESCC) in comparison to primary tumors observed by using a tissue microarray approach. Also, low expression level of CHIP was found with the better survival of ESCC cancer. Similarly, CHIP expression level is higher in gall bladder tumor tissues with the overall decreased survival of gastric cancer patients. A similar phenomenon is also observed in prostate cancer. Hence, role of CHIP in different cancers is not that much straight forward to understand. Thus, much more study is needed to be done in this area for the deeper understanding of CHIP function in tumor biology.

**Clinical significance and mechanistic details of CHIP in tumor biology**

As reported in multiple cancerous tissues, CHIP expression level varies with type and grades of cancers. To inspect the variation of CHIP expression in different cancerous tissues, we screened almost every report published till December 2020. It was also found that tissues of breast cancer patients containing higher CHIP expression have higher overall survival rate than the patients having low expression level of CHIP. The level of CHIP is up-regulated in postmenopausal breast cancerous tissues. CHIP expression level in other cancerous tissues like gastric cancer, renal cell carcinoma and non-small cell lung cancer were found to be lesser as compared to the respective normal tissues. Other cancerous tissues like glioma, gallbladder carcinoma, HBV-hepatocellular carcinoma, Head and neck cancer, and colorectal cancer tissues were reported to have an increased CHIP expression level. So, we found that CHIP has wide diversity in its expression level and differential activity in different cancer scenario. Here, authors are interested to focus on the clinical significance and the mechanistic details of CHIP in tumor biology.

**Glioma**

Malignant gliomas are studied as an invasive, aggressive, and most common primary brain tumors, having median survival time of 12–15 months for glioblastoma and 2–5 years for anaplastic glioma. In 2011, a research group has
studied the CHIP expression level in 40 glioma patient samples. Among the various histological grades of glioma, authors found increase in CHIP expression level. The enhancement of colony formation and proliferation upon CHIP overexpression, while the knockdown of CHIP gives converse results in U87 and U251 glioma cell lines. Furthermore, intra-tumoral injection of CHIP shRNA containing lentiviral particles reduced the tumor size in tumor xenografts model, while opposite results were obtained after injecting CHIP overexpressed lentiviral particles. Thus, this pioneer report demonstrated that CHIP might have a tumorigenic role in human glioma. 399 Furthermore, a report from our lab has demonstrated the tumor suppressive role of CHIP in glioma by degrading the proto-oncogenic transcription factor c-Myc through ubiquitin proteasome system. Here, we found that the N-terminal chaperone associated TPR domain of CHIP is responsible for interaction with c-Myc. Upon inhibition of HSP90 chaperone with 17-AAG, c-Myc protein level was decreased. Additionally, CHIP inhibits the transcriptional activity of c-Myc and results into reduction in malignant behavior of CHIP in C6 glioma cells, while knockdown of CHIP indicates opposite results. We demonstrated the molecular mechanism of its tumor suppressive role in glioma tumor biology. 374 These opposing reports suggests that CHIP may acts a tumor suppressor or as an oncogene in glioma tumor biology.

Breast cancer

Breast cancer is one of the most common type of malignancy in women globally where CHIP through UPS indulged in the regulation of breast cancer prognosis. 404 Till date, three clinical sample-based reports have been documented and found low expression of CHIP in breast tumor tissues than normal. Each research group concludes the overall variation in CHIP expression level. It is also noticed that breast cancer patients with increased expression of CHIP have higher overall survival rate. 375,392,393 On the other hand, in another study CHIP expression level was studied in 272 postmenopausal breast cancerous tissues and up-regulation of CHIP expression level was observed in comparison to normal tissues. 394 It is also reported that approximately 70% of primary breast cancer patients are ERα positive, 405,406 CHIP was documented to degrade the ERα upon geldanamycin induced HSP90 inhibition. 349,404,407,408 In addition to ERα, ErbB2 is also reported as a biomarker of breast cancer tissues. High expression of ErbB2 is also observed in 30% of primary breast cancer patients. 409–411 CHIP is involved in ubiquitination and degradation of ErbB2. HSP90 inhibition leads to dissociation of ErbB2 from HSP90 chaperone complex and possible shifting to the HSP90 related HSP70 chaperone. Unfortunately, HSP70 associated E3 ligase CHIP hijacks ErbB2 and promotes its ubiquitination and degradation. 173,320,392,412–415 CHIP knockdown breast cancer cells was significantly enhanced invasiveness. But this enhanced invasiveness in CHIP knockdown breast cancer cells was significantly reduced upon NF-κB inhibition. Thus, these results suggest that CHIP is indulged in the regulation of TRAF2-NF-κB signaling pathway which leads cell invasion to metastasis in breast cancer. 60,416,417

Prostate cancer

Prostate cancer is a second most cause of cancer associated deaths among the men in USA. 421 A research group screened 90 prostate cancer patient samples for CHIP expression profiling and found that CHIP is highly expressed in prostate cancer tissues compared to the normal sample. 391 Androgen
receptor (AR) is highly expressed in prostate cancer and has crucial roles in prostate cancer progression. Thus, targeting androgen receptor may be an attractive therapeutic strategy against prostate cancer. Recently a research group has documented the molecular mechanism of CHIP mediated ubiquitination and degradation of androgen receptor. They also observed that AR and CHIP interacts with each other through HSP70 chaperone.\(^1\) Furthermore, we established that CHIP degrades tumor suppressor protein PTEN in prostate cancer samples and cell lines. We also reported that TPR domain of CHIP is primarily responsible for interaction with PTEN. CHIP mediated down-regulation of PTEN activates the PI3K/AKT pathway that leads to enhanced proliferation and survival of prostate cancer cells.\(^2\) Thus, CHIP plays its dual role as a tumor suppressor as well as an oncogene in prostate tumor biology.

**Gastric cancer**

Most of the gastric cancer patients are diagnosed at advanced stages when tumor cells are resistant to radiotherapy and chemotherapy.\(^3\) Long time ago, a research group performed clinical sample-based CHIP expression profiling study and documented the association of reduced CHIP expression with aggressive gastric cancer phenotype and also observed the disappearance of CHIP expression in patients with high lymph node invasion. They also observed increased expression of CHIP in moderately differentiated gastric cancer samples compared to the poorly differentiated gastric cancer samples.\(^4\) Various other reports have been documented with CHIP expression profiling in variable gastric cancer samples\(^5\) (Table 1). Low CHIP expression in 100 gastric cancer patient samples was reported recently in 2019.\(^6\) Thus, from the above discussion it may be designated that CHIP may indulge in gastric cancer progression and can also serve as a significant diagnostic biomarker in gastric cancer patients.

**Gallbladder carcinoma**

Gallbladder carcinoma is typically diagnosed at later stages and is signified as a fatal disease.\(^7\) Despite of surgical resection, 10–30% of gallbladder carcinoma patients have survival rate of 5 years.\(^8\) Cyclooxygenase-2 and HIF are two molecular biomarkers of gallbladder carcinoma.\(^9\) CHIP expression profiling was done using 78 gallbladder carcinoma patient samples, found increased CHIP expression in carcinoma samples in comparison to normal gallbladder tissues and nicely demonstrated the relationship of CHIP expression level with clinico-pathological characteristics and patient survival rate.\(^10\) Retrospective investigations with large number of sample size are needed to be done, to understand the exact role of CHIP in gallbladder tumor biology.

**Esophageal squamous cell carcinoma (ESCC)**

ESCC is responsible for most of the esophageal malignant tumors, designated as most common cancer worldwide.\(^11\) To establish a molecular biomarker of ESCC, a research group has demonstrated the relationship between CHIP expression level and ESCC. They observed no significant change in CHIP expression level in ESCC primary tumors and normal epithelial tissue but increased level in ESCC metastatic lymph nodes. The higher CHIP expression in metastatic lymph nodes was found to be a prognostic factor which is not favorable in stage-III ESCC patients. CHIP expression level may represent a significant prognostic molecular biomarker in metastatic lymph nodes in ESCC.\(^12\)

No definite mechanism is established yet for its dichotomous role in any type of cancer. As discussed above in different cancers, CHIP may act as a novel therapeutic target or a diagnostic molecular biomarker. Role of CHIP varies from one type to another type of cancer. Literature review suggests that it may act as tumor suppressor or as an oncogene or even both in same cancer type with individual perspectives. Its role is totally unpredicted and solely depends upon downstream targets.

**Therapeutic perspectives**

Significance of CHIP has been studied in several pathological conditions such as neurological disorders (viz., Parkinson’s, Alzheimer’s, Huntington’s, Lafora, Atherosclerosis, Spino-cerebellar ataxia type-1 and hypogonadism), cardiac disorders, oxidative stress, muscular dystrophies, hyperthermia, bone related disorders and in cancer.\(^13\) Now a days, cancer is one of the prominent, non-curable and life-threatening disease.\(^14\) Till date, there is no definite, curable and life-saving strategy in cancer therapy.\(^15\) Furthermore, as reported till date, CHIP has its anti-tumorigenic effects by ubiquitination and degradation of several target oncoproteins in different cancers. Subsequently, it has been found that CHIP overexpression is negatively correlated with tumor growth in multiple cancers such as breast cancer and gastric cancer.\(^16\) Thus, CHIP overexpression leads to the inhibition of cancerous growth. Small molecule inhibitor of HSP90 also has anti-tumorigenic effect via stimulating the CHIP mediated degradation of oncoproteins. The reported HSP90 inhibitors in clinical trials are geldanamycin,\(^17\) 17AAG,\(^18\) AT13387,\(^19\) AUY922,\(^20\) BIIB021,\(^21\) BIIB028,\(^22\) NVP-HSP90,\(^23\) TQB3474,\(^24\) PEN8667,\(^25\) STA9090, 17DMAG,\(^26\) and XL888.\(^27\) All these compounds have tumor growth inhibitory property when used alone or in combination with standard anticancer drugs for clinical advancement (Table 2). These compounds act by blocking the ATP binding site of HSP90 which leads to CHIP mediated degradation of oncoprotein client proteins results in an anti-tumorigenic effect.\(^28\) The details of clinical advancement of these inhibitors during the period 2005–2021 are presented in Table 2. Thus, inhibition of HSP90 in combination with over-expression of CHIP may be an alternate novel and ideal anti-cancer strategy for cancer therapy.

**Basic disputes and unresolved mysteries of CHIP**

In last two decades, CHIP has been established as a distinct protein enzyme which has huge number of substrates. CHIP
interacts with its substrates through direct or indirect manner and performs a key role in various cellular processes such as apoptosis, proliferation, metabolism and in cellular signaling. In various reports, it is observed that CHIP regulates the substrate proteins in a chaperone dependent as well as in independent manner. It is still a key question to study how CHIP interacts with proteins and the selectivity in the complex cellular proteome. Further, it is

Figure 6  Chemical structures of HSP90 inhibitors. Figure depicts the chemical structures of various HSP90 inhibitors viz., geldanamycin, 17AAG, 17DMAG, IPI-504, AT13387, AUY922, SNX5422, STA9090, XL888, CUDC 305, BIIB021, KW-2478 and TAS-116, act as anti-cancer agents. All the structures were drawn by using chem draw software.
| HSP90 inhibitor | Year | Combination | Clinical status (Phases) | NCT no. | Status | Outcome/Indication | References |
|-----------------|------|-------------|--------------------------|---------|--------|--------------------|------------|
| 17AAG           | 2005 | I           | NCT00003969 C           | Advanced cancer | 434 |
|                 | 2006 | I           | NCT00003969 C           | Advanced malignancy | 436 |
|                 | 2007 | I           | NCT00003969 C           | Solid tumors | 437 |
|                 |      | II          | N/A                     | Renal cell carcinoma | 439 |
| Trastuzumab     | 2008 | I           | N/A                     | HER2-positive BC | 441 |
|                 |      | II          | N/A                     | Pediatric solid tumors | 443 |
|                 |      | II          | N/A                     | Pediatric solid tumors | 444 |
| Irinotecan      | 2009 | I           | NCT00119236 C          | Solid tumors | 445 |
|                 |      | II          | NCT00121264 C          | Multiple melanoma | 449 |
|                 |      | II          | NCT00118092 C          | Prostate cancer | 446 |
|                 |      | II          | NCT00104897 C          | Metastatic melanoma | 447 |
|                 | 2010 | I           | N/A                     | Multiple myeloma | 451 |
|                 |      | II          | N/A                     | Solid tumors | 450 |
|                 |      | II          | N/A                     | AML | 461 |
|                 | 2011 | I           | NCT00089362 C          | Advanced malignancy | 463 |
|                 |      | I           | NCT00088868 C          | Solid tumors | 442 |
|                 |      | I           | NCT00089277/NCT000888868 | AML | 464 |
| 17-DMAG         | 2010 | I           | NCT000248521 U         | Solid tumors | 465 |
|                 | 2011 | I           | N/A                     | Solid tumors | 466 |
|                 | 2012 | I           | N/A                     | CLL/ALL | 467 |
|                 | 2016 | I           | NCT01126502 W          | Solid tumors | 468 |
| AT13387         | 2015 | I           | NCT01246102 C          | Solid tumors | 469 |
|                 | 2016 | I           | NCT02627430 W          | Ovarian cancer, FTC, PPC, TNBC | 470 |
|                 | 2021 | I           | NCT02503709 A          | Solid tumors | 471 |
|                 |      | I           | NCT02898207 A          | Ovarian cancer, FTC, PPC and TNBC | 472 |
|                 |      | I           | NCT02381535 A          | SCC of the head and neck | 473 |

(continued on next page)
| HSP90 Inhibitor | Year | Combination                          | Clinical status (Phases) | NCT no.          | Status | Outcome/Indication | References |
|-----------------|------|--------------------------------------|--------------------------|-----------------|--------|--------------------|------------|
| Paclitaxel      | I    |                                      |                          | NCT02474173     | A      | TNBC               | 474        |
| AU922           | 2013 |                                      | I                        | N/A             |        |                    |            |
|                 | 2014 | 89Zr-trastuzumab/bevacizumab         | I                        | NCT01081613/NCT01081600 | C      | Breast cancer      | 476        |
| Bortezomib      | 2015 | I/ib                                 | C                        | NCT00708292     |        |                    |            |
|                 |      |                                      |                          | NCT01226732     | C      | Solid tumors       | 478        |
| Capecitabine    | 2016 | II                                   | C                        | NCT01404650     |        |                    | 479        |
|                 |      | II                                   | C                        | NCT01124864     |        | Multiple myeloma   | 477        |
|                 |      | II                                   | T                        | NCT01668173     |        | MPNs               | 481        |
|                 | 2017 | II                                   | T                        | NCT01485536     |        | Lymphoma           | 482        |
|                 | 2018 | II                                   | T                        | NCT01646125     |        | NSCLC              | 483        |
|                 | 2019 | II                                   | C                        | NCT01259089     |        | Lung ADC, NSCLC    | 484        |
|                 |      |                                      |                          | NCT01784640     |        | Solid tumors, lung cancer | 485        |
| BiBO21          | 2013 | II                                   | C                        | NCT00618319     | C      | GIST               | 486        |
|                 | 2014 | I                                    | C                        | NCT00618735     |        |                    | 487        |
| BiBO28          | 2013 | I                                    | C                        | NCT00725933     |        |                    | 488        |
| Debio0932       | 2015 | I                                    | C                        | NCT0168752      |        | Advanced cancer    | 489        |
| HSP990          | 2015 | I                                    | C                        | NCT00879905     |        |                    | 490        |
| IP1-504         | 2011 | I                                    | C                        | NCT00113204     |        | Multiple myeloma   | 491        |
|                 | 2013 | I                                    | C                        | NCT00276302     |        | GIST and sarcomas  | 492        |
|                 | 2017 | II                                   | T                        | NCT01228435     |        | Lung cancer        | 493        |
| Kw-2478         | 2014 | II                                   | C                        | NCT01063907     |        | Multiple melanoma  | 494        |
|                 | 2016 | I                                    | C                        | NCT00457782     |        | B-cell malignancy  | 495        |
| SNX-5422        | 2011 | I                                    | C                        | NCT00647764     |        | ST’s and lymphomas | 496        |
|                 | 2013 | I                                    | C                        | NCT00595686     |        | Malignant hematolgy | 497        |
|                 | 2017 | II                                   | T                        | NCT01848756     |        | HER2 positive cancers | 498        |
|                 | 2018 | II                                   | T                        | NCT02612285     |        | TP53 null cancers  | 499        |
|                 | 2019 | I                                    | T                        | NCT02973399     |        | CLL                | 500        |
| Sta-9090        | 2013 | I                                    | C                        | NCT00687934     |        | Solid tumors       | 501        |
|                 |      | II                                   | C                        | NCT01562015     |        | Advanced NSCLC     | 502        |
|                 |      | II                                   | C                        | NCT01111838     |        | Metastatic CRC     | 503        |
|                 |      | II                                   | T                        | NCT01227018     |        | Pancreas cancer    | 507        |
| Docetaxel       | 2015 | II                                   | T                        | NCT01348126     |        | Advanced NSCLC     | 504        |
|                 | 2016 | II                                   | C                        | NCT01270880     |        | Prostate cancer    | 505        |
|                 |      | I                                    | T                        | NCT02334319     |        | Head and neck cancer | 508        |
| Paclitaxel      | 2017 | II                                   | W                        | NCT02637375     |        | Breast cancer      | 509        |
|                 |      | II                                   | T                        | NCT01551693     |        | Melanoma           | 510        |
|                 | 2018 | II                                   | C                        | NCT01200238     |        | Ocular melanoma    | 511        |
| Paclitaxel/Trastuzumab | 2019 | I                                    | C                        | NCT02060253     |        | HER2-positive BC   | 512        |
|                 |      | I                                    | T                        | NCT02012192     |        | EPC, FTC and PPC   | 515        |
found that chaperones are involved in recruitment of several proteins for folding or CHIP mediated ubiquitination and degradation. Still, a doubt remains to be resolved whether other auxiliary factors like co-chaperones are involved in the substrate selection for recruitment under diseased context. Both TPR and Ubox are structural domains of CHIP, responsible for determining its functional abilities. As reported, CHIP helps in binding the ubiquitin molecule to the substrate proteins. Although, it seems to be some specific known sequence elements for CHIP mediated ubiquitination of substrates, this question is not yet answered. Additionally, CHIP is responsible for its dual actions as a co-chaperone as well as for E3/E4 ligase activity. It is a subject of study, how CHIP decides to perform its dual role inside the cells. How CHIP along with other chaperones acknowledge mis-folded proteins to be degraded, is still a crucial question to be answered. Thus, several studies needed to be conducted in this direction, for better understanding of the probable ways to pick up cellular proteins upon the background of organizational and physiological situations. Number of studies have been performed to distinguish the normal proteins from the misfolded ones, whether they are to be altered or degraded. Significant answers have not yet been found according to our current knowledge. CHIP also has its decisive roles in maintenance of cellular homeostasis and serves as a safety guard from the stress induced various diseases. Till date, major research on CHIP was focused upon its role but critical investigation about its disease specific differential regulation and gene expression is yet to be confirmed. It is urgent now to study about how and in which conditions CHIP is acting like a dual agent viz. tumor suppressor and oncogene. Thus, much work is needed to be done to resolve all these unresolved mysteries about CHIP for future perspectives.

Conclusion

CHIP acts as a central player in the multiple cellular processes including apoptosis, immunity, stress-response, inflammation, protein trafficking and morphogenesis. Its role has been convincingly studied in numerous morbid condition such as neurological disorders, cardiac diseases, bone remodeling and in cancer. Several studies indicate that CHIP can act as a dual agent like tumor suppressor as well as an oncogene in tumor biology. Furthermore, in multiple reports CHIP also manifests its defensive role by helping cells to remove deleterious forms of several proteins, especially under stress situation. Also, recent studies suggest that CHIP may be a novel therapeutic target to remove the numerous onco-proteins in multiple cancers. Thus, CHIP over-expression in combination with nano-encapsulated HSP90 inhibitors seems to be a valuable combinational strategy for next generation cancer therapy.

Author contributions

Conceived the idea and review structure: SK, MB and MKG; Wrote the manuscript: SK and MKG; Revised the manuscript: MB and MKG. All authors have read and agreed to the final draft of the manuscript.
Conflict of interests

There is no competing interest.

Funding

This work is jointly supported by the Department of Science and Technology (NanoMission: DST/NM/NT/2018/105(G); SERB: EMR/2017/000992) and HCT-Focused Basic Research (FBR), (Sanction No. 31-2(274)2020-21/Bud-II, dated 03.03.2021), CSIR, Govt. of India.

Acknowledgements

Authors are happy to acknowledge Ms. Pratyasha Ghosh, Department of Economics, Bethune College, University of Calcutta for carefully editing the manuscript.

Abbreviations

ADP Adenosine di-phosphate
AhR Aryl hydrocarbon receptor
AIF Apoptosis inducing factor
AMPK AMP-activated protein kinase
AR Androgen receptor
ASK1 Apoptosis signal-regulating kinase 1
ATP Adenosine tri-phosphate
BACE1 Beta-secretase 1
BAG 1, 2 and 3 BCL2 associated athano-Gene 1, 2 and 3
BER Base excision repair
BMAL-1 Brain and muscle ARNT-Like 1
CARMA1 Caspase recruitment domain-containing membrane-associated guanylate kinase protein-1
CASA Chaperone assisted selective autophagy
CDK4 Cyclin-dependent kinase 4
CFTR Cystic fibrosis transmembrane conductance regulator
ChAT Choline acetyltransferase
CHIP Carboxy-terminus of Hsp70-interacting protein
CK2β Casein kinase protein subunit 2β
CLEC-II C-type lectin-like type II transmembrane receptor
ClpP4 Chloroplast protease subunit P4
CMA Chaperone-mediated autophagy
CtBP2 C-terminal-binding protein 2
C-ErbB2/Neu Receptor tyrosine-protein kinase erbB-2
DDIAS DNA Damage Induced Apoptosis Suppressor
DLK Dual leucine zipper kinase
DNA Deoxy-ribose nucleic acid
E1’s Ubiquitin activating enzymes
E2’s Ubiquitin conjugating enzymes
E3’s Ubiquitin ligase enzymes
EGFR Epidermal growth factor receptor
Endo G Endonuclease G
ER Endoplasmic reticulum
ERα Estrogen receptor alpha
ERKs Extracellular-signal-regulated kinase
EZH2 Enhancer of zeste homolog 2
eIF4E Eukaryotic translation initiation factor 4E
eIF5A Eukaryotic translation initiation factor 5A
FADD FAS-associated via death domain
FGFR3 Fibroblast growth factor receptor 3
FMRI Fragile X mental retardation 1
FOXO1 Forkhead box protein O1
Foxp3 Forkhead box P3
GHR Growth hormone receptor
GHS Gorden holmes syndrome
GR Glucocorticoid receptor
Gas Gα, alpha subunit
HIV Human immunodeficiency virus
HECT Homologous to the E6-AP carboxyl terminus
HDAC6 Histone deacetylase 6
HERG human Ether-a-go-go-Related Gene
HIF1α Hypoxia inducible factor-1 alpha
HIP Hsp70-interacting protein
HIPK2 Homeodomain-interacting protein kinase 2
HOP Hsp70-Hsp90 organizing protein
HSP70, 40, 72, 40 and 90 Heat shock protein-70, 40, 72, 40 and 90
hPXR T408D mutant Phosphomimetic mutation at threonine-408
hTERT human Telomerase reverse transcriptase
IA Intracranial aneurysm
ICER Inducible cAMP Early Repressor
IL-4 Intracellular signal-activated kinase
IRE1 Inositol-requiring enzyme 1
IRF-1 Interferon regulatory factor 1
IR54 Insulin receptor substrate 4
ISG15 Interferon-stimulated gene 15
JNK C-jun N-terminal kinase
KCNQ4 potassium voltage-gated channel subfamily KQT member 4
LKB1 liver kinase B1
LRK2 Leucine rich repeat kinase 2
MAP3 Mitogen-activated protein kinase 3
MAST1 Microtubule-associated serine/threonine-protein kinase 1
MEKK Mitogen-activated protein kinase kinase
MIF Migration inhibitory factor
MJD Machado-joseph disease
MLK3 Mixed-lineage kinase-3
MLK4β Mixed lineage kinase 4β
MZF1 Myeloid Zinc Finger 1
mHtt Mutant Huntington
Niemann-Pick C1 Niemann-pick disease, type C1
NIK NF-kB-inducing kinase
| NEAT1 | Nuclear factor of activated T-cells, cytoplasmic 1 |
|-------|-------------------------------------------------|
| NOX4  | NADPH oxidase 4                                 |
| NPM-ALK| Nucleophosmin-Anaplastic lymphoma kinase         |
| NQO1  | NAD(P)H dehydrogenase [quinone] 1               |
| NUCB1 | Nucleobindin 1                                  |
| OCT4  | Octamer-binding transcription factor 4           |
| OTUD1 | OTU Ubiquitinase 1                              |
| PABPN1| Poly(A) binding protein nuclear 1               |
| Pae1R | Parkin associated endothelin like receptor       |
| PINK1 | PTEN-induced kinase 1                           |
| PI3K  | Phosphoinositide 3-kinase                       |
| PKC-ζ| Protein kinase C, zeta type                     |
| PKM2  | Pyruvate kinase M2                               |
| PolyQ | Polyglutamine tract                             |
| PRMT1,15| Protein arginine methyl-transferase 1, 15      |
| PrPC  | Cellular Prion Protein                          |
| PPARγ | Peroxisome proliferator-activated receptor γ    |
| PTK6  | Protein Tyrosine Kinase 6                       |
| PTEN  | Phosphatase and tensin homolog                   |
| p65   | Transcription factor p65 (RELA)                 |
| p38MAPK| p38 mitogen-activated protein kinases           |
| p42 Ebp1| Tumor suppressor p42, ErbB3-binding protein 1  |
| phosphatase PPP3CA| Serine/threonine-protein phosphatase 2B catalytic subunit alpha | |
| RHBD2 | Rhsomboid 5 Homolog 2                           |
| RFX-1 | Regulatory factor X-1                           |
| RIG-1  | Retinoic acid-inducible gene I                  |
| RING  | Really interesting new gene                     |
| RIPK3 | Receptor-interacting serine/threonine-protein kinase 3 |
| RNF216| Ring finger protein 216                         |
| RUNX1 and 2| Runt-related transcription factor 1 and 2     |
| SCAR16| Spinocerebellar ataxia autosomal recessive type 16 |
| SENP3 | Sentrin/SUMO-specific protease                   |
| SOD2  | Superoxide dismutase 2                         |
| SGK1 and 3| Serum/glucocorticoid regulated kinase 1 and 3   |
| SirT6 | Sirtuin 6                                      |
| SHP-1 | Src homology region 2 domain-containing phosphatase-1 |
| SMAD 1 and 3| Small mothers against dpp 1 and 3             |
| SNPH  | Syntaphilin                                     |
| SRC-3 | Steroid receptor coactivator-3                 |
| STAT4 | Signal transducer and activator of transcription 4 |
| STUB1 | STIP1 homology and Ubox containing protein 1    |
| Tat   | Trans-activator of transcription                |
| TAL1/Scl| stem cell leukemia/T-cell acute lymphoblastic leukemia 1 |
| TAp73x| p73x antibody specifically recognizes human and monkey full-length p73x (TAp73x) protein |
| TEAD4 | TEA Domain Transcription Factor 4              |
| TFEB  | Transcription factor EB                         |
| TLR   | Toll-like receptor                              |
| TNFα  | Tumor necrosis factor alpha                     |
| TPR   | Tetratricopeptide                               |
| TRAF3 | TNF-receptor-associated factor 3                |
| UPS   | Ubiquitin proteasome system                     |
| XRCC1 | X-ray repair cross complementing group-1        |
| 17AAG | 17-N-allylamino-17-demethoxygeldanamycin        |
| 17DMAG| 17-Dimethylaminoethylin-17-demethoxygeldanamycin |
| β-APP | β-amyloid precursor protein                     |
| (i, n, e)NOS| (inducible, neuronal, endotheial) Nitric oxide synthase |

### Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendir.2021.08.003.

### References

1. Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. *Curr Top Med Chem*. 2006;6(11):1215–1225.
2. Ellis RJ, Hemmingsen SM. Molecular chaperones: proteins essential for the biogenesis of some macromolecular structures. *Trends Biochem Sci*. 1989;14(8):339–342.
3. Martin J, Hartl FU. Molecular chaperones in cellular protein folding. *Bioessays*. 1994;16(9):689–692.
4. Loureiro J, Ploegh HL. Antigen presentation and the ubiquitin-proteasome system in host–pathogen interactions. *Adv Immunol*. 2006;92:225–305.
5. Amm I, Sommer T, Wolf DH. Protein quality control and elimination of protein waste: the role of the ubiquitin–proteasome system. *Biochim Biophys Acta BBA-Mol Cell Res*. 2014;1843(1):182–196.
6. Chiechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. *EMBO J*. 1998;17(24):7151–7160.
7. Roos-Mattjus P, Sistonen L. The ubiquitin-proteasome system in normal and disease states. *J Am Soc Nephrol*. 2006;17(7):1807–1819.
8. Roos-Mattjus P, Sistonen L. The ubiquitin-proteasome system. *Biochim Biophys Acta*. 2004;1695(1):1–2.
9. Maupin-Furlow JA, Wilson HL, Kaczowka SJ, Ou MS. Proteasomes in the archaea: from structure to function. *Front Biosci*. 2000;5:D837–D865.
10. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. *J Biol Chem*. 2006;31(1):137–155.
11. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiquitubin chain assembly. *Cell*. 1999;96(5):635–644.
12. Hershko A, Chiechanover A. The ubiquitin system. *Annu Rev Biochem*. 1998;67:425–479.
13. Johnson ES, Bartel B, Seufert W, Varshavsky A. Ubiquitin as a degradation signal. *EMBO J*. 1992;11(2):497–505.
16. Johnson ES, Ma PC, Ota IM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem. 1995;270(29):17442–17456.

17. Lee I, Schindelin H. Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell. 2008;134(2):268–278.

18. Olsen SK, Lima CD. Structure of a ubiquitin E1-E2 complex: insights to TPR or not to TPR? Trends Biochem Sci. 2010;35(2):87–96.

19. Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascade. Nature. 1995;373(6509):81–83.

20. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol. 2000;11(3):141–148.

21. Xu P, Duong DM, Seyfried NT, et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell. 2009;137(1):133–145.

22. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012;22(8):407–417.

23. Kim M, Liu X, Klionsky DJ. SnapShot: selective autophagy. Cell. 2013;152(2-3):368–368.e2.

24. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. 2018;19(6):365–381.

25. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.

26. Edkins AL. CHIP: a co-chaperone for degradation by the proteasome. Subcell Biochem. 2015;78:219–242.

27. Paul I, Ghosh MK. The E3 ligase CHIP: insights into its structure and regulation. BioMed Res Int. 2014;2014:918183.

28. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetrastricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol. 1999;19(6):4535–4545.

29. Scheffner C, Brinker A, Bourenkov G, et al. Structure of TPR domain–peptide complexes: critical elements in the assembly of the Hsp70–Hsp90 multichaperone machine. Cell. 2000;101(2):199–210.

30. Allan RK, Ratajczak T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress Chaperones. 2011;16(4):353–367.

31. Lamb JR, Tugendreich S, Hieter P. Tetrastric peptide repeat interactions: to TPR or not to TPR? Trends Biochem Sci. 1995;20(7):257–259.

32. Reva B, Antipin Y, Sander C. Predicting the functional impact of coding mutations in the ubiquitin gene in intracranial aneurysm patients of Chinese Han nationality. Asian Pac J Cancer Prev APJCP. 2013;14(3):1687–1689.

33. Shi CH, Schioler JC, Rubel CE, et al. Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP. Hum Mol Genet. 2014;23(4):1013–1024.

34. Sudarsky L, Coutinho P, Machado-Joseph disease. Clin Neuropathol. 1995(5):17–22.

35. Durr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996;39(4):490–499.

36. de Roux N, Carel JC, Léger J. Congenital hypogonadotropic hypogonadism: a trait shared by several complex neurodevelopmental disorders. Endocr Dev. 2016;29:72–86.

37. Ferreira JV, Fófo H, Bejarano E, et al. STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. Autophagy. 2013;9(9):1349–1366.

38. Siokrisky S, Boguski MS, Goebel M, Hieter P. A repeating amino acid motif in CDC23 defines a family of proteins and a new relationship among genes required for mitosis and RNA synthesis. Cell. 1990;60(2):307–317.

39. Das AK, Cohen PW, Barford D. The structure of the tetrastricopeptide repeats of protein phosphatase 5: implications for TPR-mediated protein–protein interactions. EMBO J. 1998;17(5):1192–1199.

40. McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones. 2003;8(4):303–308.

41. Zhang H, Amick J, Chakravarti R, et al. A bipartite interaction between Hsp70 and CHIP regulates ubiquitination of chaperoned client proteins. Structure. 2015;23(3):472–482.

42. Rosser MF, Washburn E, Muchowski PJ, Patterson C, Cyr DM. Chaperone functions of the E3 ubiquitin ligase CHIP. J Biol Chem. 2007;282(31):22267–22277.

43. Nikolay R, Wiederkehr T, Rist W, Kramer G, Mayer MP, Bukau B. Dimerization of the human E3 ligase CHIP via a coiled-coil domain is essential for its activity. J Biol Chem. 2004;279(4):2673–2678.

44. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem. 2001;276(35):33111–33120.

45. Hatakeyama S, Nakayama KI. U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun. 2003;302(4):635–645.

46. Passmore LA, Barford D. Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem J. 2004;379(Pt 3):513–525.

47. Arvind L, Koonin EV. The U box is a modified RING finger—a common domain in ubiquitination. Curr Biol. 2000;10(4):R132–R134.

48. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001;3(1):100–105.

49. Imai Y, Soda M, Hatakeyama S, et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson’s disease, and enhances its ubiquitin ligase activity. Mol Cell. 2002;10(1):55–67.

50. Belova L, Sharma S, Brickley DR, Nikolarsen JR, Patterson C, Conzen SD. Ubiquitin-proteasome degradation of serum-and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperone-dependent E3 ligase CHIP. Biochem J. 2006;400(2):235–244.

51. Liu F, Zhou J, Zhou P, Chen W, Guo F. The ubiquitin ligase CHIP inactivates NFκB signaling and impairs the ability of...
migration and invasion in gastric cancer cells. *Int J Oncol.* 2015;46(5):2096–2106.
59. Shang Y, Zhao X, Xu X, et al. CHIP functions an E3 ubiquitin ligase of Runx1. *Biochim Biophys Res Commun.* 2009;386(1):242–246.
60. Li X, Huang M, Zheng H, et al. CHIP promotes Runx2 degragation and negatively regulates osteoblast differentiation. *J Cell Biol.* 2008;181(6):959–972.
61. Ding X, Goldberg MS. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. *PLoS One.* 2009;4(6):e5949.
62. Kumar P, Ambasta RK, Veereshwarayya V, et al. CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism. *Hum Mol Genet.* 2007;16(7):848–864.
63. Wang Y, Mandelkow E. Degradation of tau protein by autophagy and proteasomal pathways. *Biochem Soc Trans.* 2012;40(4):644–652.
64. Qian SB, McDonough H, Boellman F, Cyr DM, Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. *Nature.* 2006;440(7083):551–555.
65. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone CHIP regulates the covalent modification of Hsp72 and Hsp90. *J Biol Chem.* 2006;281(23):23727–23734.
66. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. *Cell Mol Life Sci.* 2005;62(6):670–684.
67. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. *Cell Biol.** 2001;3(1):93–96.
68. Kundrat L, Regan L. Balance between folding and degradation regulates protein triage decisions mediated by heat-shock proteins and lysosomal pathways. *J Biol Chem.* 2005;280(25):23727–23734.
69. Marques C, Guo W, Pereira P, et al. The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones. *FASEB J.* 2006;20(6):741–743.
70. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. *Science.* 1999;286(5446):1888–1893.
71. Strickland E, Qu BH, Millen L, Thomas PJ. The molecular chaperone Hsc70 assists the in vitro folding of the N-terminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator. *J Biol Chem.* 1997;272(41):25421–25424.
72. Landry SJ, Giersch LM. Polypeptide interactions with molecular chaperones and their relationship to in vivo protein folding. *Annu Rev Biophys Biomol Struct.* 1994;23(1):645–669.
73. Cheetham ME, Jackson AP, Anderton BH. Regulation of 70-kDa heat-shock-protein ATPase activity and substrate binding by human DnaJ-like proteins, HSJ1a and HSJ1b. *Eur J Biochem.* 1994;226(1):99–107.
74. Hiromura M, Yano M, Morii H, Inoue M, Kido H. Intrinsic ADP-ATP exchange activity is a novel function of the molecular chaperone, Hsp70. *J Biol Chem.* 1998;273(10):5435–5438.
75. Kettern N, Dreisidegger M, Tawo R, Höhfeld J. Chaperone-assisted degradation: multiple paths to destruction. *Biol Chem.* 2010;391(5):481–489.
76. Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality control. *Science.* 2016;353(6294):aae4354.
77. Mayer MP. Hsp70 chaperone dynamics and molecular mechanisms. *Trends Biochem Sci.* 2013;38(10):507–514.
78. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. *Annu Rev Biochem.* 2001;70(1):603–647.
79. Kriegenburg F, Ellgaard L, Hartmann-Petersen R. Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation. *FEBS J.* 2012;279(4):532–542.
80. Esser C, Alberti S, Höhfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. *Biochim Biophys Acta.* 2004;1695(1–3):171–188.
81. Höhfeld J, Cyr DM, Patterson C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. *EMBO Rep.* 2001;2(10):885–890.
82. Meimarisou E, Gooljar SB, Chapell JP. From hitching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery. *J Mol Endocrinol.* 2009;42(1):1–9.
83. Dem Jan, Alberti S, Patterson C, Höhfeld J. Cooperation of a ubiquitin domain protein and an ubiquitin ligase during chaperone/proteasome coupling. *Curr Biol.* 2001;11(20):1569–1577.
84. Nieder J, Dem Jan, Höhfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. *J Biol Chem.* 2000;275(7):4613–4617.
85. Arndt V, Dick N, Tawo R, et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. *Curr Biol.* 2010;20(2):143–148.
86. Alberti S, Esser C, Höhfeld J. BAG-1 a nucleotide exchange factor of Hsc70 with multiple cellular functions. *Cell Stress Chaperones.* 2003;8(3):225–231.
87. Dong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. *J Biol Chem.* 2003;278(31):28490–28500.
88. Gassler CS, Wiederkehr T, Brehmer D, Bukau B, Mayer MP. Bag-1M accelerates nucleotide release for human Hsc70 and Hsp70 and can act concentration-dependent as positive and negative cofactor. *J Biol Chem.* 2001;276(35):32538–32544.
89. Wiederkehr T, Bukau B, Buchberger A. Protein turnover: a CHIP programmed for proteolysis. *Curr Biol.* 2002;12(11):R26–R28.
90. Gamerdinger M, Hajleva P, Kaya AM, Wolfrum U, Hartl FU, Behl C. Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. *EMBO J.* 2009;28(7):889–901.
91. Arndt V, Daniel C, Nastainczyk W, Alberti S, Höhfeld J. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. *Mol Biol Cell.* 2005;16(12):5891–5900.
92. Schönuber B, Schmitt V, Huesmann H, Kern A, Gamerdinger M, Behl C. BAG2 interferes with CHIP-mediated ubiquitination of HSP72. *Int J Mol Sci.* 2016;18(1):69.
93. Stankiewicz M, Nikolay R, Rybin V, Mayer MP. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. *FEBS J.* 2010;277(16):3353–3367.
94. García-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. *Lancet Oncol.* 2013;14(9):e358–e369.
95. Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. *Mol Cell Biol.* 1995;15(12):6804–6812.
96. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. *Exp Biol Med (Maywood).* 2003;228(2):111–133.
97. Young JC, Maarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. *J Cell Biol.* 2001;154(2):267–274.
98. Zhan S, Wang T, Ge W. Multiple functions of the E3 ubiquitin ligase CHIP in immunity. *Int Rev Immunol.* 2017;36(5):300–312.
100. Li RF, Zhang F, Lu YJ, Sui SF. Specific interaction between Smad1 and CHIP: a surface plasmon resonance study. Colloids Surf B Biointerfaces. 2005;40(3–4):133–136.

101. Xin H, Xu L, Li L, et al. CHIP controls the sensitivity of transforming growth factor-β signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem. 2005;280(21):20842–20850.

102. Shao M, Li L, Song S, et al. E3 ubiquitin ligase CHIP interacts with C-type lectin-like receptor CLEC-2 and promotes its ubiquitin-proteasome degradation. Cell Signal. 2016;28(10):1530–1536.

103. Wang T, Wang W, Wang Q, Xie R, Landay A, Chen D. The E3 ubiquitin ligase CHIP in normal cell function and in disease conditions. Ann N Y Acad Sci. 2020;1460(1):3–10.

104. Xu Z, Kohli E, Devlin KI, Bold M, Nix JC, Misra S. Inhibitory function of CHIP in mammalian cells. BMC Struct Biol. 2008;8:26.

105. Page RC, Pruneda JN, Amick J, Klevit RE, Misra S. Structural insights into the conformation and oligomerization of E2 ubiquitin conjugates. Biochimie. 2012;94(20):4175–4187.

106. Narayan V, Pion E, Landrê V, Müller P, Ball KL. Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP. J Biol Chem. 2011;286(1):607–619.

107. Soss SE, Yue Y, Dhe-Paganon S, Chazin WJ. E2 conjugating enzyme selectivity and requirements for function of the E3 ubiquitin ligase CHIP. J Biol Chem. 2011;286(24):21277–21286.

108. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrates through sequential ubiquitylation and proteasomal targeting. Cell. 2005;120(1):73–84.

109. Hoppe T. Multiquitylation by E4 enzymes: ‘one size doesn’t fit all’. Trends Biochem Sci. 2005;30(4):183–187.

110. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair enzymes. Annu Rev Biochem. 2006;75:587–594.

111. Caldecott KW, McKeown CK, Tucker JD, Ljungquist S, Lindahl T, Wood RD. Quality control by DNA repair. Cell Mol Life Sci. 2002;59(18):2331–2346.

112. Sancar A, Sancar GB. DNA repair enzymes. Annu Rev Biochem. 1988;57:29–67.

113. Lindahl T, Wood RD. Quality control by DNA repair. Science. 1999;286(5446):1897–1905.

114. Wood RD, Mitchell M, Sgoouros J, Lindahl T. Human DNA repair genes. Science. 2001;291(5507):1284–1289.

115. Parsons JL, Tait PS, Finch D, Dianova I, Allison SL, Dianov GL. CHIP-mediated degradation and DNA damage-dependent stabilization regulate base excision repair proteins. Mol Cell. 2008;29(4):477–487.

116. Lee JS, Yoo SJ. C-terminal of Hsc70-interacting protein regulates C-terminal binding protein 2 and the expression of its substrate multiubiquitylation and proteasomal targeting. Cell Physiol Biochem. 2014;34(6):1361–1372.

117. Burg MB, Ferraris JD, Dmitrieva NL. Cellular response to hyperosmotic stresses. Physiol Rev. 2007;87(4):1441–1474.

118. Maruyama T, Kadowaki H, Okamoto N, et al. CHIP-dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic response. EMBO J. 2010;29(15):2501–2514.

119. Morey TM, Drink Ng W, Seah C, Rylett RJ. Chaperone-mediated regulation of activity of choline acetyltransferase protein stability and activity by HSC/HSP70, HSP90, and p97/VCP. Front Mol Neurosci. 2017;10:415.
137. Gao B, Wang Y, Xu W, Li S, Li Q, Xiong S. Inhibition of histone deacetylase activity suppresses IFN-γ induction of tripartite motif 22 via CHIP-mediated proteasomal degradation of IRF-1. J Immunol. 2013;191(1):464–471.

138. Gao Z, Li Y, Wang F, et al. Mitochondrial dynamics controls anti-tumour innate immunity by regulating CHIP-IRF7 axis stability. Nat Commun. 2017;8(1):1805.

139. Landré V, Pion E, Narayan V, Xiromirdas DP, Ball KL. DNA-binding regulates site-specific ubiquitination of IRF-1. Biochem J. 2013;449(3):707–717.

140. Wang X, DeFranco DB. Alternative effects of the ubiquitin-ligase CHIP: A double agent in cancer. Cell. 2017;171(3):673.

141. Biswas K, Sarkar S, Said N, Brautigan DL, Larner JM. Aurora B E3 ligase CHIP: A double agent in cancer. Nature. 2017;20(1):127.

142. Bento CF, Fernandes R, Ramalho J, et al. The chaperone-assisted E3 ubiquitin ligase STUB1, which functions as an AKAP.

143. Im S, Kim DW. Nkx3.2 induces oxygen concentration-dependent ubiquitin. J Biol Chem. 2019;295(14):4696–4708.

144. Schisler JC, Rubel CE, Zhang C, Lockyer P, Cyr DM, Patterson C. CHIP protects against cardiac pressure overload through regulation of AMPK. J Clin Invest. 2013;123(8):3588–3599.

145. Ravalin M, Theofilius P, Basu K, et al. Specificity for latent C termini links the E3 ubiquitin ligase CHIP to caspases. Nat Chem Biol. 2019;15(8):786–794.

146. Shen G, Yan J, Pasapula V, et al. The chloroplastic protease subunit ClpP4 is a substrate of the E3 ligase AtCHIP and plays an important role in chloroplast function. Plant J. 2007;49(2):228–237.

147. Kim SM, Grenert JP, Patterson C, Correia MA. CHIP(-/-) mouse liver: adiponectin-AMPK-FOXO-activation overrides CYP2E1-elicited JNK1-activation, delaying onset of NASH: therapeutic implications. Sci Rep. 2016;6:29423.

148. Wang Y, Guan S, Acharya P, et al. Ubiquitin-dependent proteosomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination. J Biol Chem. 2011;286(11):9443–9456.

149. Wang Y, Guan S, Acharya P, et al. Multisite phosphorylation of human liver cytochrome P450 2A4 enhances its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction. Mol Cell Proteomics. 2012;11(2):M111.010132.

150. Wang Y, Kim S-M, Trnka MJ, Liu Y, Burlingame AL, Correia MA. The chaperone human liver cytochrome P450 2A4 ubiquitination: molecular recognition by UbC7-gp78 autocrine motility factor receptor and UbCh5a-Chip-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes. J Biol Chem. 2015;290(6):3308–3332.

151. Tsvetkov P, Adamovich Y, Elliott E, Shaul Y. E3 ligase STUB1/CHIP regulates NAD (P) H: quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients. J Biol Chem. 2011;286(11):8839–8845.

152. Jiang B, Shen H, Chen Z, Yin L, Zan L, Rui L. Carboxyl terminus of HSC70-interacting protein (CHIP) down-regulates NF-κB-inducing kinase (NIK) and suppresses NIK-induced liver injury. J Biol Chem. 2015;290(18):11704–11714.

153. Ahmed SF, Deb S, Paul I, et al. The chaperone-assisted E3 ligase CHIP targets PTEN for proteasomal degradation. J Biol Chem. 2012;287(19):15996–16006.
173. Xu W, Marcu M, Yuan X, Minnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002;99(20):12847–12852.

174. Sun S-C. Non-canonical NF-κB signaling pathway. Cell Res. 2011;21(1):71–85.

175. Yin L, Wu L, Wesche H, et al. Defective lymphotxin-β receptor-induced NF-κB transcriptional activity in NIH-deficient mice. Science. 2001;291(5511):2162–2165.

176. Willmann KL, Klaver S, Doğu F, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360.

177. Zarnegar BJ, Wang Y, Mahoney DJ, et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008;9(12):1371–1378.

178. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Semin Immunol. 2007;19(1):71–85.

179. Ali A, Farooqui SR, Banerjea AC. The host cell ubiquitin ligase protein CHIP is a potent suppressor of HIV-1 replication. J Biol Chem. 2019;294(18):7283–7295.

180. Kim R, Eme M, Tanabe K. Cancer immunoeediting: from immune surveillance to immune escape. Immunology. 2007;121(1):1–14.

181. Jackaman C, Bundell CS, Kinnear BF, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003;171(10):5051–5063.

182. Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. Oncogene. 2010;29(48):6301–6313.

183. LiH, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101(4):805–815.

184. Zhao K, Zhang Q, Li X, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008;20(11):1467–1479.

185. Seo J, Lee EW, Sung H, et al. CHIP controls necroptosis formation suppressing cell death. Cell. 2016;164(9):2112.

186. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

187. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Ann Rev Med. 2015;66:1–17.

188. Kpringe DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(1):33–46.

189. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70(20):3813–3827.

190. Hannahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

191. Strauss L, Sangaleetti S, Consonni FM, et al. RORC1 regulates tumor-promoting “emergency” granulo-monocytosis. Cancer Cell. 2015;25(9):325–330.

192. Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.

193. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70(20):3813–3827.

194. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.

195. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008;180(4):2011–2017.

196. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2010;184(2):702–712.

197. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.

198. Szebeni GJ, ViziCZ, Kitajka K, Puskas LG. Inflammation and cancer: extra- and intracellular determinants of tumor-associated macrophages as tumor promoters. Mediators Inflamm. 2017;2017:e9294018.

199. Jackaman C, Yeoh TL, Acuit ML, Gardner JK, Nelson DJ. Murine mesothelioma induces locally-proliferating IL-10(+) TNF-
E3 ligase CHIP: A double agent in cancer

α(+) CD206(-) CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy. Oncol Immunology. 2016;5(6):e1173299.

214. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555.

215. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717–727.

216. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A. 2012;109(7):2491–2496.

217. De Palma M. Origins of brain tumor macrophages. Cancer Cell. 2016;30(6):832–833.

218. Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res. 2010;70(14):5728–5739.

219. Shand FH, Ueha S, Otsuji M, et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc Natl Acad Sci U S A. 2014;111(21):7771–7776.

220. Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–182.

221. Beaudoin S, Goggin K, Bissonnette C, Grenier C, Roucou X. Aggresomes do not represent a general cellular response to protein misfolding in mammalian cells. BMC Cell Biol. 2008;9:59.

222. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143(7):1883–1898.

223. Sha Y, Pandit L, Zeng S, Eissa NT. A critical role for CHIP in the aggresome pathway. Mol Cell Biol. 2009;29(1):116–128.

224. Luciani A, Villetta VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol. 2010;12(9):863–875.

225. Dickey CA, Patterson C, Dickson D, Petrucelli L. Brain CHIP: removing the culprits in neurodegenerative disease. Trends Mol Med. 2007;13(1):32–38.

226. Petrucelli L, Dickson D, Kehoe K, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004;13(7):703–714.

227. Kanack AJ, Newsom OJ, Scaglione KM. Most mutations that cause spinocerebellar ataxia autosomal recessive type 1 destabilize the protein quality-control E3 ligase CHIP. Mol Cell Neurosci. 2018;714:1–14.

228. Beaudoin S, Goggin K, Bissonnette C, Grenier C, Roucou X. Aggresomes do not represent a general cellular response to protein misfolding in mammalian cells. BMC Cell Biol. 2008;9:59.

229. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem. 2004;279(6):4869–4876.

230. Rao SH, Sharma J, Maitly R, Jana NR. Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease. J Biol Chem. 2010;285(2):1404–1413.

231. Choi YN, Jeong DH, Lee JS, Yoo SJ. Regulation of fragile X mental retardation 1 protein by C-terminus of Hsc70 rich repeat kinase-2 ubiquitination, degradation, and aggregation. J Biol Chem. 2018;293(12):17962–17974.

232. Dickey CA, Koren J, Zhang YJ, et al. Akt and CHIP coregulate intracellular degradation of LRRK2. Biochem J. 2015;474(9):1547–1558.

233. Rees I, Lee S, Kim H, Tsai FT. The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner. Biochim Biophys Acta BBA. 2006;1764(6):1073–1079.

234. Al-Ramahi I, Lam YC, Chen HK, et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem. 2006;281(36):26714–26724.

235. Rudenko IN, Kaganovich A, Langston RG, et al. The G2385R risk factor for Parkinson’s disease enhances CHIP-dependent intracellular degradation of LRRK2. Biochem J. 2017;474(9):1547–1558.

236. Ko HS, Bailey R, Smith WW, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A. 2009;106(8):2897–2902.

237. Hirayama S, Yamazaki Y, Kitamura A, et al. MKKS is a centrosome-shuttling protein degraded by CHIP and phosphorylation-dependent ubiquitination. Mol Biol Cell. 2008;19(3):899–911.

238. Yoo L, Chung KC. The ubiquitin E3 ligase CHIP promotes pro-teasomal degradation of the serine/threonine protein kinase PINK1 during staurosporine-induced cell death. J Biol Chem. 2018;293(4):1286–1297.

239. Dimant H, Zhu L, Kibuuka LN, Fan Z, Hyman BT, McLean PJ. Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One. 2014;9(3):e92098.

240. Tetzlaff JE, Putcha P, Uetreito TF, et al. CHIP targets toxic α-synuclein oligomers for degradation. J Biol Chem. 2008;283(26):17962–17968.

241. Choi YN, Jeong DH, Lee JS, Yoo SJ. Regulation of fragile X mental retardation 1 protein by C-terminus of Hsc70 interacting protein depends on its phosphorylation status. Biochem Biophys Res Commun. 2014;453(1):192–197.

242. Zhao T, Hong Y, Yin P, Li S, Li XJ. Differential HspBP1 expression accounts for the greater vulnerability of neurons than astrocytes to misfolded proteins. Proc Natl Acad Sci U S A. 2017;114(7):E7803–E7811.

243. Saidi L-J, Polidoro M, Kay KR, et al. Carboxy terminal heat shock protein 70 interacting protein reduces tau-associated degenerative changes. J Alzheimers Dis. 2015;44(3):937–947.

244. Cook C, Gendron TF, Scheffel K, et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet. 2012;21(13):2936–2945.

245. Dickey CA, Koren J, Zhang YJ, et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A. 2008;105(9):3622–3627.

246. Grune T, Botzen D, Engel M, et al. Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys. 2010;500(2):181–188.
263. Wang T, Li S, Yi D, et al. CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells. *Biochem Biophys Res Commun.* 2013;430(2):500–504.

255. Clapp KM, Peng HM, Morishima Y, et al. C331A mutant of the endoplasmic reticulum stress in tauopathy. *Biochem Biophys Res Commun.* 2004;321(3):574–583.

253. Miller LM, D’esposito M. Perceptual fusion and stimulus coincidence in the cross-modal integration of speech. *J Neurosci.* 2005;25(25):5884–5893.

258. Branicky R, Hekimi S. Proteostasis or aging: let the CHIPs fall. *Mol Cell Biol.* 2010;20(12):3767–3778.

252. Sakagami Y, Kudo T, Tanimukai H, et al. Involvement of CHIP up-regulation attenuating tau aggregation. *J Neurochem.* 2005;94(5):1254–1263.

254. Singh AK, Pati U. CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of β-secretase. *Aging Cell.* 2015;14(4):595–604.

251. Sahara N, Murayama M, Mizoroki T, et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. *J Neurochem.* 2005;94(5):1254–1263.

259. Jana NR, Dikshit P, Goswami A, et al. Co-chaperone CHIP as a STUB-strat for proteasome-based degradation of familial ALS-linked mutant Cu/Zn-superoxide dismutase proteins. *Mol Pharmacol.* 2009;26(10):1814–1824.

256. Matsumoto K, Nishiya T, Maekawa S, et al. The ECS (SPSB) E3 ubiquitin ligase is the master regulator of the lifetime of inducible nitric-oxide synthase. *Biochem Biophys Res Commun.* 2011;409(1):46–51.

257. Choi JS, Cho S, Park SG, Park BC, Lee DH. Co-chaperone CHIP associates with mutant Cu/Zn-superoxide dismutase proteins linked to familial amyotrophic lateral sclerosis and promotes their degradation by proteasomes. *Biochem Biophys Res Commun.* 2004;321(3):574–583.

250. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. *Am J Respir Crit Care Med.* 2002;165(1):255–261.

251. Miller LM, D’esposito M. Perceptual fusion and stimulus coincidence in the cross-modal integration of speech. *J Neurosci.* 2005;25(25):5884–5893.

258. Branicky R, Hekimi S. Proteostasis or aging: let the CHIPs fall. *Mol Cell Biol.* 2010;20(12):3767–3778.

252. Sakagami Y, Kudo T, Tanimukai H, et al. Involvement of CHIP up-regulation attenuating tau aggregation. *J Neurochem.* 2005;94(5):1254–1263.

254. Singh AK, Pati U. CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of β-secretase. *Aging Cell.* 2015;14(4):595–604.
precursor degradation through the ubiquitin-26S proteasome system in Arabidopsis. Plant Cell. 2009;21(12):3984–4001.

291. Hoiermakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–1485.

292. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705.

293. Zinger A, Cho WC, Ben-Yehuda A. Cancer and aging. Mech Ageing Dev. 2017;165 (Pt A):10–16.

294. Li P, Kurata Y, Maharani N, et al. E3 ligase CHIP and Hsc70: A double agent in cancer. Cancer Sci. 2016;6(5):675–681.

295. Kimura T, Uesugi M, Takase K, Miyamoto N, Sawada K. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway. Toxicol Appl Pharmacol. 2017;329:282–292.

296. Chung HY, Kim HJ, Jung KJ, et al. The inflammatory process in aging. Ageing Res Rev. 2007;6(4):1436–1441.

297. Crow MT. Revisiting P53 and its Effectors in Ischemic Heart Injury. J Mol Cell Cardiol. 2009;46(6):705–712.

298. Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;5(4):1537–1546.

299. Torain A, Wright MH, Gandhi B, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminomethyl)amino]-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Toxicol Appl Pharmacol. 2007;228(1):16–24.

300. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol. 2011;22(5):1011–1018.

301. Alberti R, Caramanti M, Savini A, et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol. 2013;88(1):75–86.

302. Chen ZL, Al DI. Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol. 2016;4(5):675–681.

303. Pecoraro M, Sorrentino R, Franceschelli S, Del Pizzo M, Pinto A, Popolo A. Doxorubicin-mediated cardiotoxicity: role of mitochondrial connexin 43. Cardiovasc Toxicol. 2015;15(4):366–376.

304. Robbins AI, Wright MH, Gandhi B, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminomethyl)amino]-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res. 2006;12(21):6547–6556.

305. Crow MT. Revisiting P53 and its Effectors in Ischemic Heart Injury. J Mol Cell Cardiol. 2009;46(6):705–712.
Biochim Biophys Acta BBA-Mol Cell Res. 2007;1773(3):383–390.

331. Lee JH, Khadka P, Baek SH, Chung IK. CHIP promotes human telomerase reverse transcriptase degradation and negatively regulates telomerase activity. J Biol Chem. 2010;285(3):4203–42045.

332. Lei H, Jin J, Liu M, et al. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells. Leuk Res. 2018;64:17–23.

333. Huang H, Weng H, Dong B, Zhao P, Zhou H, Qu L. Oridonin triggers chaperone-mediated proteasomal degradation of BCR-ABL in leukemia. Sci Rep. 2017;7:41525.

334. Kang SA, Cho HS, Yoon JB, Chung IK, Lee ST. Hsp90 rescues p42 Ebp1 regulates the pro-proliferative activity of EGFR. Oncogene. 2014;33(26):3123–3143.

335. Wang X, Cao W, Zhang J, et al. Covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. J Cell Biochem. 2017;169(9):1243–1260.

336. Wang T, Yang J, Xu J, et al. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Oncotarget. 2014;5(7):1969–1986.

337. Hou J, Deng Q, Zhou J, et al. Csn6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 2017;36(8):1134–1144.

338. Wang X, Cao W, Zhang J, et al. CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation. Biochem Biophys Res Commun. 2016;479(2):152–158.

339. Lee JH, Khadka P, Baek SH, Chung IK. CHIP promotes estrogen receptor α levels in ovariectomised rats: mechanisms and implications for memory. J Neuroendocrinol. 2016;28(10):10.1111/jne.12429.

340. Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and galdanamycin-induced degradation of estrogen receptor-α. Mol Endocrinol. 2005;19(12):2901–2914.

341. Tateishi Y, Sonoo R, Sekiya Y, et al. Turning off estrogen receptor β-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol. 2006;26(21):7966–7976.

342. Zhang X, Qian SB. Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes. Mol Cell Biol. 2011;21(18):3277–3288.

343. Shang Y, Zhao X, Tian B, et al. CHIP/Stub1 interacts with elf5A and mediates its degradation. Cell Signal. 2014;26(5):1098–1104.

344. Li X, Zhang L, Wang Z, et al. Phosphorylation of IRS4 by CK1ε promotes its degradation by CHIP through the ubiquitin/vlyosome pathway. Theranostics. 2018;8(13):3643–3653.

345. Blessing NA, Brockman AL, Chadee DN. The E3 ligase CHIP mediates ubiquitination and degradation of mixed-lineage kinase 3. Mol Cell Biol. 2014;34(16):3123–3143.

346. Ko HR, Kim CK, Lee SB, et al. P42 Ebp1 regulates the proteasomal degradation of the p58 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death Dis. 2014;5(1):e1131.

347. Nie L, Wu H, Sun XH. Ubiquitination and degradation of Tal1/SCL are induced by notch signaling and depend on Skp2 and CHIP. J Biol Chem. 2008;283(2):684–692.

348. Terme JM, Lhermitte L, Asnafi V, Jalninot P. TGF-β induces degradation of Tal1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation. Blood J Am Soc Hematol. 2009;113(26):6695–6698.

349. Kim S, Ham S, Yang K, Kim K. Protein kinase CK2 activation triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia. Mol Biol Cell. 2017;28(1):41525.

350. Min B, Park H, Lee S, et al. CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer. Oncogene. 2016;35(28):3718–3728.

351. Blessing NA, Kasturirangan S, Zink EM, Schroyer AL, Chadee DN. Osmotic and stress-dependent regulation of MLK4 and MLK3 by the CHIP E3 ligase in ovarian carcinoma. Cell Signal. 2016;79(7):1098-e1098.

352. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxy-geldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 2004;64(9):3256–3264.

353. Kang SA, Cho HS, Yoon JB, Chung IK, Lee ST. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells. Biochem J. 2012;447(2):313–320.

354. Dhamad AE, Zhou Z, Zhou J, Du Y. Systematic proteomic identification of the heat shock proteins (Hsp) that interact with estrogen receptor alpha (ERα) and biochemical characterization of the ERα-Hsp70 interaction. PLoS One. 2016;11(8):e0160312.

355. Wu H, Yao S, Zhang S, et al. Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma. J Hepatol. 2017;66(6):1193–1204.

356. Black KL, Witty CF, Daniel JA. Previous midlife oestriol treatment results in long-term maintenance of hippocampal oestrogen receptor α levels in ovariectomised rats: mechanisms and implications for memory. J Neuroendocrinol. 2016;28(10):10.1111/jne.12429.

357. Park SM, Park SH, Ryu KJ, et al. Downregulation of CHIP promotes ovarian cancer metastasis by inducing Snail-mediated epithelial–mesenchymal transition. Mol Oncol. 2019;13(5):1280–1295.

358. Won KJ, Im JY, Kim BK, et al. Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells. Cell Death Dis. 2018;9(1):e2554.

359. Li D, Marchenko ND, Schulz, et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant
stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9(5):577–588.
368. Kweyrr-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galectone and VNPT55 induce pro teaseal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of ca stration resistant prostate cancer xenografts in vivo. Oncotarget. 2015;6(29):27440–27460.
369. Wang J, Zhang H, Zhang X, et al. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity. Oncotarget. 2016;7(49):81377–81388.
370. Moon SJ, Jeong BC, Kim HJ, Lim JE, Kwon GY, Kim JH. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. Oncogene. 2018;37(10):1326–1339.
371. Sarkar S, Brautigan DL, Parsons SJ, Larner JM. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene. 2014;33(1):26–33.
372. Sarkar S, Brautigan DL, Larner JM. Aurora kinase A promotes AR degradation via the E3 ligase CHIP. Mol Cancer Res. 2017; 15(8):1063–1072.
373. Su CH, Lan KH, Li CP, et al. Phosphorylation accelerates geldanamycin-induced Akt degradation. Arch Biochem Bio phys. 2013;536(1):6–11.
374. Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32(10):1284–1295.
375. Patani N, Jiang W, Newbold R, Mokbel K. Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer. J Cancer Res. 2010;9;9.
376. Ahmed SF, Das N, Sarkar M, Chatterjee U, Chatterjee S, Ghosh MK. Exosome-mediated delivery of the intrinsic C-termi nus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesis. Mol Ther. 2015;23(2):255–269.
377. Li F, Xie P, Fan Y, et al. C terminus of Hsc70-interacting protein promotes smooth muscle cell proliferation and sur vival through ubiquitin-mediated degradation of FoxO1. J Biol Chem. 2009;284(30):20900–20908.
378. Choi JR, Shin KS, Choi CY, Kang SJ. PARP1 regulates the protein stability and proapoptotic function of HIPK2. Cell Death Dis. 2016;7(10),e2438.
379. Han SY, Ko A, Kitano H, et al. Molecular chaperone HSP90 is neces sary to prevent cellular senescence via lysosomal degradation of p14ARF. Cancer Res. 2017;77(2):343–354.
380. Biswas K, Sarkar S, Du K, Brautigan DL, Abbas T, Larner JM. The E3 ligase CHIP mediates p21 degradation to maintain radioresistance. Mol Cancer Res. 2017;15(6):651–659.
381. Shang Y, Xu X, Duan X, et al. Hsp70 and Hsp90 oppositely regulate TGF-β signaling through CHIP/Stub1. Biochem Biophys Res Commun. 2014;446(1):387–392.
382. Choi YN, Lee SK, Seo TW, Lee JS, Yoo SJ. C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration. Biochem Biophys Res Commun. 2014;446(4): 1060–1066.
383. Sane S, Hafner A, Srinivasan R, et al. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortal1-2 in cancer cells. Mol Oncol. 2018;12(10):1753–1777.
384. Canaff L, Vanbellinghen JF, Kanazawa I, et al. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. J Clin Endocrinol Metab. 2012;97(2):E282–E291.
385. Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394–402.
386. Niki T, Tsutsui S, Hirose S, et al. Galec tin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem. 2009;284(47): 32344–32352.
387. Gaude H, Aznar N, Delay A, et al. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene. 2012;31(12):1582–1591.
388. Tanwar K, Pati U. Inhibition of apoptosis via CHIP-mediated proteasomal degradation of Tap73. J Cell Biochem. 2019; 120(7):11091–11103.
389. Wen J, Luo KJ, Hu Y, Yang H, Fu JH. Metastatic lymph node CHIP expression is a potential prognostic marker for resected esophageal squamous cell carcinoma patients. Ann Surg Oncol. 2013;20(5):1668–1675.
390. Liang ZL, Kim M, Huang SM, Lee HJ, Kim JM. Expression of car boxyl terminus of Hsp70-interacting protein (CHIP) indi cates poor prognosis in human gallbladder carcinoma. Oncol Lett. 2013;5(3):813–818.
391. Cheng L, Zang J, Dai HJ, Li F, Guo F. Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer. Int J Oncol. 2018;53(1): 203–214.
392. Jan CI, Yu CC, Hung MC, et al. Tid1, CHIP and ErbB2 in teractions and their prognostic implications for breast cancer patients. J Pathol. 2011;225(3):424–437.
393. Xu J, Wang H, Li W, et al. E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells. Clin Exp Med. 2020;20(1):109–119.
394. Kurozumi S, Yamaguchi Y, Hayashi SI, et al. Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med. 2016;5(8):1873–1882.
395. Gan L, Liu DB, Lu HF, et al. Decreased expression of the carboxyl terminus of heat shock cognate 70 interacting pro tein in human gastric cancer and its clinical significance. Oncol Rep. 2012;28(4):1392–1398.
396. Wang S, Wu X, Zhang J, et al. CHIP functions as a novel sup pressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 2013;62(4):496–508.
397. Sun C, Li H, Chen H, et al. Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma. Sci Rep. 2015;5:9774.
398. Qian T, Wang J, Wang Q, et al. CHIP involves in non-small cell lung cancer prognosis through VEGF pathway. Biomed Phar macother. 2016;83:271–276.
399. Xu T, Zhou Q, Zhou J, et al. Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci. 2011;102(5):959–966.
400. Jin Y, Zhou L, Liang ZY, Jin KM, Zhou WX, Xing BC. Clinico-pathologic and prognostic significance of carboxyl terminus of Hsp70-interacting protein in HBV-related hepatocellular carci noma. Asian Pac J Cancer Prev APJCP. 2015;16(9): 3709–3713.
401. Xiao M, Yan M, Zhang J, Xu Q, Chen W. Carboxy-terminus Hsc70 interacting protein exerts a tumor inhibition func tion in head and neck cancer. Oncol Rep. 2017;38(3): 1629–1636.
402. Xu J, Zhou J, Dai H, et al. CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin. J Transl Med. 2018;16(1):169.
403. Wen P, Kesarl S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.
404. Yi X, Wei W, Wang SY, Du ZY, Yu YJ, Yu XD. Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol. 2008;75(9):1697–1705.
405. Allred DC, Mohsin SK. Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia. 2000;5(4):351–364.

406. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481.

407. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18(3):306–360.

408. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003;9(13):4961–4971.

409. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409–1411.

410. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29(3):231–245.

411. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative factor family tyrosine kinases. J Biol Chem. 2001;276(5):3702–3708.

412. Mimauga EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor tyrosine kinase induced by geldanamycin. J Biol Chem. 1996;271(37):22796–22801.

413. Miller P, DiOrio C, Moyer M, et al. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. 1994;54(10):2724–2730.

414. Zheng FT, Kuduk SD, Chiosis G, et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000;60(8):2090–2094.

415. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569–581.

416. Park BK, Zhang H, Zeng Q, et al. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med. 2007;13(1):62–69.

417. Chen S, Guttridge DC, Tang E, Shi S, Guan K, Wang CY. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/Smad signaling. J Biol Chem. 2001;276(42):39259–39263.

418. Wu CJ, Conze DB, Li X, Ying SX, Hanover JA, Ashwell JD. TNF-α induced c-IAP1/TRAF2 complex translocation to an UbC6-containing compartment and TRAF2 ubiquitination. EMBO J. 2005;24(10):1886–1898.

419. Habelhah H, Frew LJ, Laine A, et al. Stress-induced decrease in TRAF2 stability is mediated by Siah2. EMBO J. 2002;21(21):5756–5765.

420. Jemal A, Siegel R, Ward E, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249.

421. Prins GS, Sklarew R, Pertschuk LP. Image analysis of 17-allylamino-17-demethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90, in patients with advanced malignancies. J Clin Oncol. 2005;23(18):4152–4161.

422. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17(allylamo)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005;23(9):1885–1893.

423. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23(6):1078–1087.

424. Ramanathan RK, Trump DL, Eisenman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17(allylamo)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005;11(9):3385–3391.

425. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17(allylamo)-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2003;21(21):4087–4095.

426. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23(6):1078–1087.

427. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17(allylamo)-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23(6):1078–1087.

428. Ramanathan RK, Trump DL, Eisenman JL, et al. Phase I pharmacokinetic and pharmacodynamic study of 17(allylamo), 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005;23(18):4152–4161.

429. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17(allylamo)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005;23(9):1885–1893.

430. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006;12(20):6087–6093.

431. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17(allylamo)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest N Drugs. 2006;24(6):543–546.

432. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17(allylamo)-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Cancer Res. 2007;13(6):1775–1782.

433. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and trastuzumab. JAMA. 2010;290(1):24–35.

434. Ramanathan RK, Trump DL, Eisenman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17(allylamo)-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23(6):1078–1087.
demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. *Clin Cancer Res.* 2007;13(6):1783–1788.

445. Tse AN, Klimstra DS, Gonen M, et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. *Clin Cancer Res.* 2008;14(20):6704–6711.

446. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. *Clin Cancer Res.* 2008;14(23):7940–7946.

447. Solit DB, Osman I, Polsky D, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. *Clin Cancer Res.* 2008;14(24):8302–8307.

448. Ramalingam SS, Egorin MJ, Ramanathan RK, et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. *Clin Cancer Res.* 2008;14(11):3456–3461.

449. Richardson PG, Badros AZ, Jagnathan S, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. *Br J Haematol.* 2010;150(4):519–528.

450. Vaishampayan UN, Burger AM, Sausville EA, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. *Clin Cancer Res.* 2010;16(14):3795–3804.

451. Robertson PG, Chanahan-Khan AA, Alsina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. *Br J Haematol.* 2010;150(4):438–445.

452. Hubbard J, Erlitchman C, Toft DO, et al. Phase I study of 17-allylamino-17-demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. *Invest New Drugs.* 2011;29(3):473–480.

453. Modi S, Stoppek A, Linden H, et al. HSPP90 inhibition is effective in breast cancer: a phase II trial of tamespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. *Clin Cancer Res.* 2011;17(15):5132–5139.

454. Kaufmann SH, Karp JE, Litzow MR, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. *Haematologica.* 2011;96(11):1619–1626.

455. Iyer G, Morris MJ, Rathkopf D, et al. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. *Cancer Chemother Pharmacol.* 2012;69(4):1089–1097.

456. Hendrickson AE, Oberg AL, Glaser G, et al. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. *Gynecol Oncol.* 2012;124(2):210–215.

457. Richardson PG, Chanahan-Khan AA, Lonial S, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or refractory multiple myeloma: results of a phase 1/2 study. *Br J Haematol.* 2011;153(6):729–740.

458. Gartner EM, Silverman P, Simon M, et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. *Breast Cancer Res Treat.* 2012;131(3):933–937.

459. Pacey S, Gore M, Chao D, et al. A Phase II trial of 17-allylamo-17-demethoxygeldanamycin (17-AAG, taneispimycin) in patients with metastatic melanoma. *Invest N Drugs.* 2012;30(1):341–349.

460. Schenk E, Hendrickson AE, Northfelt D, et al. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. *Invest N Drugs.* 2013;31(5):1251–1256.

461. Walker AR, Klisovic R, Johnston JS, et al. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma.* 2013;54(9):1996–2002.

462. Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlitchman C, McWilliams RR. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. *Invest N Drugs.* 2015;33(4):963–968.

463. Kummar S, Gutierrez ME, Gardner ER, et al. Phase I trial of 17-demethylnooethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. *Eur J Cancer.* 2010;46(2):340–347.

464. Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. *Leukemia.* 2010;24(4):699–705.

465. Pacey S, Wilson RH, Walton M, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. *Clin Cancer Res.* 2011;17(6):1561–1570.

466. Jhaveri K, Miller K, Rummert L, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. *Clin Cancer Res.* 2012;18(18):5090–5098.

467. Maddocks K, Hertlein E, Chen TL, et al. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. *Leuk Lymphoma.* 2016;57(9):2212–2215.

468. Do K, Speranza G, Chang LC, et al. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. *Invest N Drugs.* 2015;33(4):921–930.

469. Shapiro GI, Kwak E, Dezube BJ, et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSPP90 inhibitor, AT13387, in patients with advanced solid tumors. *Clin Cancer Res.* 2015;21(1):87–97.

470. National Cancer Institute (NCI). A Phase 1 Study of PARP Inhibitor BMN 673 and HSPP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer. 2016.

471. National Cancer Institute (NCI). A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSPP90) Inhibitor Olaparib (AT13387) and the Cyclin-dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors; 2021.

472. National Cancer Institute (NCI). A Phase 1 Study of PARP Inhibitor Olaparib and HSPP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer; 2021.

473. National Cancer Institute (NCI). A Phase I Trial of AT13387 in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCHHN) Receiving Concurrent Radiation and Cisplatin; 2021.

474. National Cancer Institute (NCI). Phase 1b Study of HSPP90 Inhibitor, AT13387 (Onalespib) in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer; 2021.

475. Sessa C, Shapiro GI, Bhalla KN, et al. First-in-human phase I dose-escalation study of the HSPP90 inhibitor AUY922 in patients with advanced solid tumors. *Clin Canc Res.* 2013;19(13):3671–3680.

476. Gaykema SB, Schröder CP, Vitfell-Rasmussen J, et al. 89Z-trastuzumab and 89Z-bevacizumab PET to evaluate the
effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. *Clin Cancer Res*. 2014;20(15):3945–3954.

Ssegwiss-Bernhardt R, Bargou RC, Goh YT, et al. Phase 1/1 B trial of the heat shock protein 90 inhibitor NVP-AUY 922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. *Cancer*. 2015;121(13):2185–2192.

SCRI Development Innovations, LLC. A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors; 2015.

SCRI Development Innovations, LLC. A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients Eth Re- fractory Gastrointestinal Stromal Tumor; 2016.

Novartis Pharmaceuticals. A Phase II, Multi-Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Patients with Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemo therapy; 2016.

Memorial Sloan Kettering Cancer Center. A Phase I/II trial of the HSP90 inhibitor, AUY922, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF) and refractory PV/ET; 2016.

Anderson Cancer Center MD. A Phase II Study of the HSP90 Inhibitor AUY922 In Patients with Relapsed and Refractory Lymphoma; 2016.

Novartis Pharmaceuticals. A Multicenter, Open-Label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients with EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment; 2019.

Northwestern University. A Phase I/II Trial of HSP 90 Inhibitor AUY-922 in Patients with Lung Adenocarcinoma with "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors; 2019.

Jonsson Comprehensive Cancer Center. A Phase IB Dose-Escalation study of Pemetrexed and AUY922 in Previously-Treated Patients with Metastatic Non-squamous, Non-small Cell Lung Cancer; 2020.

Dickson MA, Okuno SH, Keohan ML, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. *Ann Oncol*. 2013;24(1):252–257.

Salf MW, Takimoto C, Mita M, et al. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. *Clin Cancer Res*. 2014;20(2):445–455.

Hong D, Said R, Falchook G, et al. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. *Clin Cancer Res*. 2013;19(17):4824–4831.

Isambert N, Delord JP, Soria JC, et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer results of a first-in-man dose-escalation study with a fixed-dose extension phase. *Ann Oncol*. 2015;26(5):1005–1011.

Spreafico A, Delord JP, De Mattos-Arruda L, et al. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. *Br J Cancer*. 2015;112(4):650–659.

Siegel D, Jagannath S, Vesole DH, et al. A phase 1 study of IPI-504 (retasipimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. *Leuk Lymphoma*. 2011;52(12):2308–2315.

Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the Hsp90 inhibitor retasipimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. *Clin Cancer Res*. 2013;19(21):6020–6029.

Sequist LV. A Phase II Study of IPI-504, A Novel Hsp90 Inhibitor in NSCLC Patients with ALK Translocations; 2017.

Kyowa Hakko Kirin Pharma, Inc. An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed And/or Refractory Multiple Myeloma; 2014.

Yong K, Cavet J, Johnson P, et al. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. *Br J Cancer*. 2016;114(1):7–13.

Rajan A, Kelly RJ, Trepel JB, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. *Clin Cancer Res*. 2011;17(21):6831–6839.

Reddy N, Voorhees PM, Houk BE, Brega N, Hinson Jr JM, Jillela A. Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. *Clin Lymphoma, Myeloma & Leukemia*. 2013;13(4):385–391.

Esanex Inc. A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects with Selected HER2 Positive Cancers; 2016.

Esanex Inc. A Single Arm Study of SNX-5422 in Subjects with TP53 Null Cancers; 2018.

Esanex Inc. A Phase 1, Open-Label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects with Residual Disease; 2016.

Goldman JW, Raju RH, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. *BMC Cancer*. 2013;13:152.

Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genetically defined advanced non–small cell lung cancer. *Clin Cancer Res*. 2013;19(11):3068–3077.

Cercek A, Shia J, Gollub M, et al. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. *Clin Colorectal Cancer*. 2014;13(4):207–212.

Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). *Ann Oncol*. 2015;26(8):1741–1748.

Thakur MK, Heilbrun LK, Sheng S, et al. A phase II trial of ganetespib, a heat shock protein 90Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. *Invest N Drugs*. 2016;34(1):112–118.

Pillai RN, Fennell DA, Kovcin V, et al. Randomized phase III study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non–small cell lung cancer (GALAXY-2). *J Clin Oncol*. 2020;38(6):613–622.

MD DC. Phase II Study of STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer; 2014.

Saba NF. A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN); 2016.

University of Chicago. A Pilot Preoperative Trial of Ganetespib with Paclitaxel for Triple-Negative Breast Cancer; 2016.

MD FSH. This trial is an open label, parallel cohort, phase II study evaluating the efficacy of the heat shock protein 90 (HSP90) inhibitor STA-9090 in patients with 1546 S. Kumar et al. unsectable stage III or stage IV melanoma who were intolerant of, or progressed on, prior tyrosine kinase inhibitor treatment. Two cohorts will enroll concurrently. One cohort will be composed of patients with melanoma expressing a mutation in the potein BRAF and the other cohort will be composed of patients with melanoma expressing wild-type BRAF; 2017.
51. MD FSH. A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma; 2018.
52. Memorial Sloan Kettering Cancer Center. A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination with Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer; 2018.
53. MD AC. Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-squamous Non-small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas; 2018.
54. MD AC. Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-squamous Non-small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas. 2018.
55. Concin N. A Two-Part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination with Paclitaxel Weekly in Women with High-Grade Serous, High-Grade Endometrioid, or Undifferentiated, Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer; 2019.
56. Sarcoma Alliance for Research through Collaboration. A Phase Ia/Ib Trial of Ganetespib in Combination with the MTOR Inhibitor Sirolimus for Patients with Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors; 2019.
57. M.D AC. Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients with Refractory Solid Tumors and Low-Grade Non-hodgkin’s Lymphoma; 2017.
58. Samus Therapeutics, Inc. Phase 1b Study of PU-H71 for the Treatment of Subjects with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis Post-ET MF), Treated with Ruxolitinib; 2020.
59. Taiho Oncology, Inc. A Phase IA/IB Study Evaluating TAS-116 in Patients with Advanced Solid Tumors; 2019.
60. Centre Hospitalier Universitaire Dijon. Preclinical Project on the Treatment of Acute Lymphoblastic Leukemia with NVP-Bep800, an Inhibitor of the Heat Shock Protein HSP90; 2020.
61. Bregnhoej A. A Phase 1b, Open-Label, Single-Arm, Dose-Selection, Proof-Of-Concept Study to Assess the Safety and Efficacy of a Novel HSP90 Inhibitor (CLUC-305) in the Treatment of Moderate to Severe Plaque Psoriasis; 2019.
62. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection; 2019.
63. Tarveda Therapeutics. A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients with Advanced Solid Malignancies; 2021.
64. Reata Pharmaceuticals, Inc. A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults; 2017.
65. El-Rayes B. Phase Ib Trial of Pembrolizumab and XL888 in Patients with Advanced Gastrointestinal Malignancies; 2021.
66. H. Lee Moffitt Cancer Center and Research Institute. Phase I Study of Escalating Doses of XL888 with Vemurafenib Plus Cobimetinib for Patients with Unresectable BRAF Mutated Stage III/IV Melanoma; 2021.
67. Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updates. 2009; 12(1–2):17–27.